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The ability to therapeutically manipulate regulatory T (Treg) cell survival/function 
would have far reaching implications; with the potential to limit immune pathology in 
autoimmune disease, allergy and transplantation; and to reduce regulation of anti-
tumour responses in cancer. This study has established a method to study the 
survival and function of antigen specific Treg cells in vivo, adapting an existing 
approach in which an endogenous naïve T cell population is expanded and tracked. 
Multiple immunisation of antigen, and an agonistic anti-DR3 antibody were used to 
ensure a sufficient number and proportion of Treg cells could be expanded. Further 
to this, an assay for investigating Treg cell function in vivo was applied to this system. 
This approach revealed that the tumour necrosis factor receptors OX40 and CD30 
may play a role in Treg function, as well as expansion. Unexpectedly, these data also 
revealed that in the absence of OX40 there is a gross defect in the function of CD4 T 
cells. A regulatory role of group 3 Innate Lymphoid cells is emerging in the literature, 
and in accordance with this, this study demonstrates that Treg cell expansion is 
grossly impaired in mice which lack RORγt, their lineage defining transcription factor.  
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1.1 Introduction to immune responses 
The immune system, which has evolved to protect against infection, is typically 
divided into innate and adaptive components. If a pathogen is able to breach the 
barrier surfaces of the body, the cells of the innate immune system recognise 
common pathogen components, known as pathogen associated molecular patterns 
(PAMPs) (Janeway and Medzhitov, 2002). Upon recognition via their pathogen 
recognition receptors (PRRs), phagocytes such as macrophages become activated 
and engulf and destroy bacteria. In addition, these cells secrete pro-inflammatory 
cytokines which promote inflammation and facilitate immune cell accumulation. In 
contrast, the cells of the adaptive immune system, B and T lymphocytes, recognise 
specific epitopes or peptides and there is a delay of several days before they are 
able to contribute to the response. Dendritic cells are considered to be the key cell in 
initially driving adaptive immune responses as they are able to activate T cells 
through presentation of cognate antigen to their T cell receptors (TCR) (Banchereau 
and Steinman, 1998). These antigen-presenting cells do so in the context of major 
histocompatibility (MHC) molecules, of which there are two classes. MHC class I 
molecules are expressed by all nucleated cells and present endogenous antigens, 
such as viral peptides to the TCR of T cells expressing the co-receptor CD8, also 
known as cytotoxic T cells when activated. Importantly, antigen-presenting cells can 
also present peptides derived from the local environment. These peptides are 
presented on MHC class II (MHC II) molecules, to T cells expressing the co-receptor 
CD4, also known as T helper (Th) cells when activated. During a bacterial infection 
for example, bacteria are phagocytosed and processed into peptides which are 




1.2 T cell tolerance  
To ensure protection from a wide range of pathogens, humans have evolved the 
capacity to generate 108 different TCR (Arstila et al., 1999) each of which can 
recognise up to a million different peptides (Sewell, 2012). To gain this level of 
diversity, T (and B cell) receptors are generated through a process called V(D)J 
recombination, in which coding regions are assembled from germline Variable (V), 
Diversity (D) and Joining (J) segments (Tonegawa, 1983, Hesslein and Schatz, 
2001). This process is dependent on recombination activating genes (RAG)-1 and -2 
and therefore in their absence T cells cannot develop (Mombaerts et al., 1992, 
Shinkai et al., 1992). This process results in a high level of diversity because multiple 
combinations can be assembled from the pool of V, D and J segments, and variation 
is introduced during segment ligation (Bassing et al., 2002). During this process, 
however, there is the potential that TCR are generated which can recognise self-
peptides. To safeguard against the development of autoimmune disease there is 
therefore the need for multiple layers of T cell tolerance. These can be broadly split 
into central tolerance, which occurs during T cell development through a process 
called negative selection, and peripheral tolerance which is mediated by a number of 
mechanisms in the periphery. 
1.2.1 Central tolerance 
The precursors of T cells are generated in the bone marrow, but develop in the 
thymus. Lymphoid progenitors enter the thymus at the cortico-medullary junction as 
double negative thymocytes (CD4-CD8-), and migrate through the cortex, where they 




rearranged and if successful, CD4 and CD8 are upregulated and TCR α-chain 
rearrangement occurs. Positive selection selects for CD4+CD8+ (double positive) 
thymocytes bearing TCR that can recognise peptide in the context of MHC II. This 
therefore ensures that T cells which progress have the capacity to become activated 
by antigen-presenting cells such as dendritic cells in the periphery (Laufer et al., 
1996). Double positive thymocytes which survive positive selection downregulate 
either CD4 or CD8 to become single positive cells. Negative selection is mediated by 
medullary thymic epithelial cells (mTECs) as well as dendritic cells, which present 
self-peptides in the context of MHC II molecules and mediate the clonal deletion of 
thymocytes bearing TCR with high affinity for these peptides (Gallegos and Bevan, 
2004). mTECs are able to express tissue specific antigens due to the activity of the 
transcription factors Autoimmune regulator (AIRE) and Fezf2 (Derbinski et al., 2001, 
Takaba et al., 2015). Negative selection ensures that only (conventional) T cells with 
low affinity for self-peptide enter the periphery, and is therefore a mechanism of 
maintaining tolerance to self-antigens (Starr et al., 2003). It is important however, that 
the process of negative selection does not delete all potentially self-reactive T cells 
as there is a need to strike the balance between removing these cells and ensuring 
that there is a wide enough repertoire to protect us from infection. There is therefore 
the need for mechanisms to maintain tolerance in the periphery.  
1.2.2 Peripheral tolerance 
There are multiple layers of peripheral tolerance, of which a key checkpoint is the 
requirement for co-stimulation in T cell activation. T cells exit the thymus as naïve 
CD4 or CD8 T cells, and recirculate around the blood stream, passing through 




Mempel, 2003). These secondary lymphoid tissues increase the chances of a 
lymphocyte meeting its cognate antigen by providing specialised microenvironments 
with discrete areas for T and B cell activation. Lymph nodes are positioned at the 
junctions of lymphoid vessels, which transport antigen and activated antigen-
presenting cells through the lymph to the lymph nodes from the site of infection.  
CD4 T cell activation requires multiple signals and results in IL-2 production and 
proliferation (Smith-Garvin et al., 2009). The first signal is delivered through 
engagement of the TCR with its cognate antigen in the context of MHC II. The 
second signal is delivered by a plethora of co-stimulatory molecules, and the third by 
cytokines, which direct differentiation into the different T helper subsets. The three 
main subsets and their lineage defining transcription factors are: Th1 cells (Tbet), 
Th2 cells (GATA-3), and Th17 cells (RORγt) (O'Shea and Paul, 2010). The existence 
of different T helper subsets allows tailoring of the immune response towards the 
type of pathogen, for example Th1 cells secrete Interferon γ (IFNγ) which promotes 
macrophage activation and therefore aids clearance of bacteria.  
Co-stimulatory ligands and MHC II are provided by antigen-presenting cells, such as 
dendritic cells, but are only upregulated upon recognition of PAMPs by PRRs such as 
Toll-like receptors (TLRs) (Banchereau and Steinman, 1998). Co-stimulatory 
receptors, which are expressed by the T cell, are divided into two subsets; the 
immunoglobulin and tumour necrosis factor (TNF) receptor super families. The initial 
costimulatory signal is delivered through interaction of the immunoglobulin 
superfamily receptor CD28, which is constitutively expressed by naïve T cells, with its 
ligands CD80 and CD86, expressed by mature dendritic cells (Lenschow et al., 




molecules including TNF receptors such as OX40, which are principally involved in 
promoting T cell survival during activation (Croft, 2009). In the absence of co-
stimulation TCR signaling results in anergy, a state of unresponsiveness. Therefore, 
the requirement for signal 2 can be considered to be a safeguard against T cell 
activation in the absence of infection, which is known as ‘passive tolerance’. This 
study will concentrate on the action of Treg cells, which is known as ‘dominant 
tolerance’ and will be explored in detail. 
1.3 Treg cells 
Treg cells are a subset of CD4 T cells which are able to suppress responses against 
self (Sakaguchi, 2004). These cells, which comprise 5-10% of the CD4 T cell 
population, have been identified both in mice (Gershon and Kondo, 1970, Sakaguchi 
et al., 1995) and humans (Baecher-Allan et al., 2001, Dieckmann et al., 2001, 
Jonuleit et al., 2001). In addition to their role in preventing autoimmunity, Treg cells 
have been shown to play an important role in maintaining oral and feto-maternal 
tolerance as well as feedback control of the immune response, particularly to reduce 
pathogen-associated immune pathology (Corthay, 2009). The role of Treg cells in 
allergy, transplantation and cancer are also of great interest in the scientific 
community, due to the potential for therapeutic manipulation. 
The identification of discriminatory markers for Treg cells is not straightforward, as 
the majority of markers are shared with activated T cells in mice and humans. These 
include CD25 (Sakaguchi et al., 1995), Cytotoxic T lymphocyte antigen 4 (CTLA-4) 
(Read et al., 2000, Takahashi et al., 2000), Lymphocyte Activation Gene 3 (LAG-3) 




2002). In mice the transcription factor forkhead/winged-helix box P3 (FOXP3) is 
considered to be the most reliable marker of Treg cells as it is exclusively expressed 
by these cells. In humans however, FOXP3 is transiently expressed in T cells upon 
activation (Gavin et al., 2006). It has been proposed that low expression of CD127 
(IL-7Rα) should be also be used to aid identification of Treg cells, particularly in 
humans (Seddiki et al., 2006, Liu et al., 2006), therefore Treg cells are generally 
characterised as FOXP3+ CD25hi CD127 (IL-7Rα)lo (Vignali et al., 2008).  
The crucial role of Treg cells in maintaining tolerance is demonstrated in mice which 
lack expression of FOXP3. These ‘scurfy’ mice develop a CD4 T cell dependent fatal 
lymphoproliferative disease (Clark et al., 1999, Brunkow et al., 2001). Similarly, if 
Treg cells are depleted after birth, the mouse will succumb to fatal lymphoproliferative 
disease within 2-3 weeks (Kim et al., 2007). This is also mirrored in the human 
disease IPEX (Immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome), which is caused by a FOXP3 mutation and is characterised by severe 
autoimmunity (Bennett et al., 2001, Wildin et al., 2002). This transcription factor has 
been shown to act both as a repressor and as an activator (Marson et al., 2007, 
Zheng et al., 2007) and has been referred to as the ‘master regulator’ of Treg cell 
generation and function (Fontenot et al., 2003, Hori et al., 2003). Although there 
appears to be little doubt over the critical role of FOXP3 in Treg cell function, its 
importance in Treg cell lineage commitment has been questioned (Gavin et al., 2007, 
Lin et al., 2007, Hill et al., 2007). In these studies, disruption of the FOXP3 locus 
revealed that it amplifies and stabilises the regulatory lineage rather than being the 




revealed that only a small proportion of the gene expression ‘signature’ of Treg cells 
can be recapitulated through FOXP3 transduction (Hill et al., 2007). 
1.3.1 Treg cell subsets 
Treg cells can either be generated in the thymus or induced in the periphery from 
naïve T cells (Bluestone and Abbas, 2003). As a result, Treg cells have been 
categorised as either thymically- (tTreg) or peripherally-derived (pTreg) (Abbas et al., 
2013), as shown in Figure 1.1. The two subsets have often been referred to as 
natural or induced Treg cells, however this has not always been consistent and can 
be deemed misleading. The term ‘natural’ infers that the second subset does not 
occur naturally, and there is the potential that the term ‘induced’ may cause 
confusion with in vitro induced Treg cells. Therefore, the terms tTreg and pTreg were 
brought in as part of a move to simplify the nomenclature. Treg cells within human 
peripheral blood can also be classified according to expression of CD45RA and 
FOXP3 (Miyara et al., 2009). CD45RA+FOXP3loTreg cells are considered to be 
‘resting’, CD45RA-FOXP3hiTreg cells ‘activated’ and CD45RA-FOXP3lo cells ‘non-
suppressive’. 
1.3.1.1 Development of tTreg cells 
Jordan et al. (2001) have demonstrated that thymic development of Treg cells 
requires high affinity interactions between the TCR and self-peptide. This study 
utilised a TCR transgenic system, demonstrating that thymocytes with low affinity for 
antigen were not able to become tTreg cells. TCR signalling is therefore thought to 
have an ‘instructive’ role in Treg cell development, and it has been suggested that 




below the threshold for negative selection but above the threshold for positive 
selection (Josefowicz et al., 2012). This reliance on antigen encounter for Treg cell 
development is evidenced in studies in which it is shown that without thymic antigen 
expression, Treg cells cannot develop (Walker et al., 2003b, Itoh et al., 1999). 
Further evidence for this comes from a study showing that mTEC, which express 
self-peptides, are crucial for Treg cell development (Cowan et al., 2013). It has also 
been demonstrated by Tai et al. (2005) that CD28 signaling is required alongside 
TCR signaling to initiate FOXP3 expression and therefore promote Treg cell 
development.  
Interestingly, a sequencing study of hundreds of TCRs has shown that Treg cells do 
not show any more bias towards self-antigens than naïve T cells, although Treg cells 
do exhibit a greater diversity of TCRs (Stephens and Shevach, 2007, Pacholczyk et 
al., 2007). Therefore, although Treg cells can recognise self-antigen, this may not be 
a cardinal feature of these cells. Consistent with this, it has also been shown that 
immunisation of peptide can lead to the development of antigen-specific Treg cells in 
the thymus of mice (Zelenay et al., 2010), which demonstrates that peripheral 
antigen can influence tTreg development.  
1.3.1.2 Development of pTreg cells  
In vitro cell culture experiments have revealed that upon activation in the presence of 
TGFβ, naïve CD4 T cells can upregulate FOXP3 (Chen et al., 2003, Fantini et al., 
2004). The pivotal role of this cytokine has subsequently been demonstrated through 
in vivo experiments, in which it was shown that pTreg cell induction was abrogated 




two subsets of pTreg cells which do not express FOXP3 (Vieira et al., 2004). These 
are the T regulatory 1 (Tr1) and T helper 3 (Th3) subsets which have been classified 
as regulatory due to their high production of IL-10 and TGFβ respectively, as well as 
their ability to suppress chronic inflammatory responses in vivo (Groux et al., 1997, 
Chen et al., 1994). Conversion to Tr1 cells has been shown to be mediated primarily 
by IL-10 rather than TGFβ (Groux et al., 1997), therefore providing a positive 
feedback loop for Tr1 generation.  
Interestingly, it has been demonstrated that naïve T cells which have recently 
entered the periphery from the thymus are most likely to be converted into pTreg 
cells (Paiva et al., 2013). pTreg cell development has been reported to be associated 
with low dose antigen (Apostolou and von Boehmer, 2004), and suboptimal activation 
of dendritic cells (Kretschmer et al., 2005). This suggests that conversion of naïve T 
cells to pTreg cells occurs more readily when there is weak co-stimulation. 
Interestingly, administration of antigen through the oral route has also been shown to 
be associated with pTreg generation (Mucida et al., 2005, Coombes et al., 2007). In 
these studies, it was shown that oral ovalbumin can induce TGFβ-dependent 
expansion of Treg cells in the mesenteric lymph nodes of mice. These studies used 
TCR transgenic (DO11.10) mice on a RAG deficient background, which are not able 
to produce tTreg cells (Walker et al., 2003b, Itoh et al., 1999), and therefore it was 
possible to demonstrate that the increase in Treg cells was due to conversion of 
naïve T cells rather than expansion of tTreg cells. This suggests pTreg cells have a 
role in oral tolerance, which interestingly has also been shown to be associated with 







Figure 1.1: Treg cell subsets. FOXP3+ Treg cells are either generated in the 
thymus from CD4+CD8- thymocytes (tTregs) or in the periphery through TGFβ-
dependent conversion of naïve CD4+ T cells (pTregs). Two subsets of FOXP3- Treg 
cells also arise from naïve CD4+ T cells in the periphery: T helper 3 (Th3) cells and T 






Haribhai et al. (2011b) have demonstrated that there is only 5-15% overlap between 
the TCR repertoire of pTreg and tTreg cells, which is perhaps unsurprising seeing 
as pTreg cells develop from conventional T cells. This suggests that there may 
functional dichotomy between these two subsets, and indeed transcriptome analysis 
of nTreg cells alongside pTreg cells generated by various routes has revealed that 
the two subsets have distinct gene expression profiles (Feuerer et al., 2010, Haribhai 
et al., 2009). Among the transcripts differentially expressed are those encoding 
chemokine receptors, effector molecules and transcription factors (Feuerer et al., 
2010) indicating that these two subsets may be specialised towards different types of 
response and/or different locations. However, Haribhai et al. (2009) have shown that 
transfer of a 1:1 mix of pTreg and tTreg cells are able to better suppress the onset of 
T cell-induced colitis than transfer of either subset independently. Therefore, despite 






1.3.1.3 Discrimination between tTreg and pTreg cells 
Helios, and more recently Neuropilin-1, have been proposed as markers for 
discriminating tTreg cells from pTreg cells (Singh et al., 2015). Helios is a 
transcription factor from the Ikaros family (Hahm et al., 1998), which has been shown 
to be expressed by all thymic Treg cells but only 70% of Treg cells in the periphery of 
both mice and humans (Thornton et al., 2010). In addition, pTreg cells induced by 
oral ovalbumin were found to be Helios-. This has however been challenged by 
multiple groups (Verhagen and Wraith, 2010, Akimova et al., 2011, Gottschalk et al., 
2012), including Himmel et al. (2013), who demonstrated that both Helios+ and 
Helios- tTreg cells can be identified in human blood. Neuropilin-1 (Nrp-1) is a 
semaphorin III receptor which was initially characterised in relation to its role within 
the nervous system (Kolodkin et al., 1997). It has subsequently been shown to be 
expressed on the surface of Treg cells where it promotes long interactions with 
antigen-presenting cells (Sarris et al., 2008). It has been proposed that it is only tTreg 
cells which express Nrp-1 as again all thymic Treg cells were found to express Nrp-1 
but only around 70% of Treg cells found in the periphery of mice. In addition, pTreg 
cells induced in the gut were shown to express lower levels of Nrp-1 than the overall 





1.3.2 Mechanisms of suppression by Treg cells 
Treg cells can suppress many different immune cells, including natural killer cells, B 
cells, dendritic cells, monocytes and T cells (Schmidt et al., 2012). Their main 
function is often considered to be suppression of naïve T cell activation, which is 
thought to be by influencing both the naïve T cell, and the antigen-presenting cell 
(Schmidt et al., 2012), as shown in Figure 1.2. This ultimately leads to reduction in 
IL-2 production by the T cell, and therefore impaired proliferation (Thornton and 
Shevach, 1998, Takahashi et al., 1998). Interestingly Treg cells have also been 
shown to suppress effector and memory T cells (Levings et al., 2001), although they 
are thought to be more effective at suppressing the activation of naïve T cells (Miyara 
and Sakaguchi, 2007). Treg cells require stimulation through their TCR, as well as IL-
2, for their activity (Thornton et al., 2004a, Thornton et al., 2004b) and thus are 
considered to be activated in an antigen specific manner. However, numerous 
studies have shown that they can suppress T cells of multiple specificities, which is 
termed bystander suppression (Thornton and Shevach, 2000, Takahashi et al., 1998, 
Thornton and Shevach, 1998). It is important to note however, that Treg cells may 




















































































































































































































































































Figure 1.2: Treg cell-mediated suppression of T cells. The suppressive 
mechanisms employed can be divided into four categories: reduced T cell activation, 
metabolic disruption, immunomodulatory mediators and cytolysis/cell cycle arrest. 
Treg: Regulatory T cell, CTLA-4: Cytotoxic T lymphocyte antigen 4, LAG-3: 
Lymphocyte activation gene 3, CD: Cluster of differentiation, MHC II: Major 
histocompatibility complex class II, DC: Dendritic cell, IDO: indoleamine 2, 3-
dioxygenase, ATP: adenosine triphosphate, AMP: adenosine monophosphate, ICER: 
inducible cAMP early repressor, cAMP: cyclic adenosine monophosphate, A2AR: A2A 





1.3.2.1 Reduced T cell activation 
Multiple mechanisms have been described for Treg cell-mediated suppression, which 
can be divided into four categories. The first results from interactions between Treg 
and dendritic cells, which have been shown to occur in vivo by intravital microscopy 
by multiple groups (Tang et al., 2006, Tadokoro et al., 2006). Interestingly Nrp-1, 
which has previously been discussed as a marker of tTreg cells, has been shown to 
promote long interactions between Treg cells and dendritic cells (Sarris et al., 2008), 
and therefore may give Treg cells an advantage over T cells.  
One of the key mechanisms of Treg cell-mediated suppression is thought to be 
through the action of CTLA-4, particularly as selective depletion of this inhibitory 
receptor from Treg cells results in lymphoproliferative disease (Wing et al., 2008, 
Friedline et al., 2009). CTLA-4 is constitutively expressed by Treg cells (Takahashi et 
al., 2000, Read et al., 2000, Metzler et al., 1999) and shares its ligands CD80 and 
CD86 with the co-stimulatory receptor CD28. As CTLA-4 binds with higher affinity to 
these ligands than CD28, it has been proposed that the mechanism by which CTLA-4 
interferes with T cell activation is by out-competing CD28 for binding to its ligands 
(Masteller et al., 2000). However, it has been shown that CTLA-4, which cycles 
between the surface and cytoplasm, can ‘rip’ CD80/86 from the surface of dendritic 
cells through a process called trans-endocytosis, which results in the degradation of 
these ligands within the Treg cell (Qureshi et al., 2011). This would suggest that 
rather than competing with CD28 for its ligands, CTLA-4 depletes CD80/86 from 
dendritic cells and as a result there is less available to bind CD28 and deliver signal 2 
for T cell activation. It has also been proposed that reverse signaling occurs as a 




enzyme indoleamine 2, 3-dioxygenase (IDO) within the dendritic cell (Grohmann et 
al., 2002). This enzyme converts tryptophan to kynurenine, which is thought to result 
in inhibition of T cell proliferation due to the resulting shortage of tryptophan within 
the microenvironment (Mellor et al., 2002) and may cause T cell apoptosis due to the 
toxicity of kynurenine (Fallarino et al., 2003). 
Another inhibitory receptor, LAG-3, has also been shown to interfere with T cell 
activation, by blocking the maturation of dendritic cells (Liang et al., 2008). As 
dendritic cell maturation crucially leads to the upregulation of co-stimulatory 
molecules and MHC II, this would prevent T cell activation. LAG-3 is upregulated on 
Treg cells upon activation and participates in their suppressive function (Huang et al., 
2004, Workman and Vignali, 2005). LAG-3 is able to bind to MHC II with higher 
affinity than CD4 (Huard et al., 1995), with which it shares structural homology, and it 
is thought to be via this interaction that LAG-3 provides inhibitory signals to dendritic 
cells (Liang et al., 2008). 
1.3.2.2 Metabolic disruption 
Various suppressive mechanisms have been proposed which interfere with naïve T 
cell or dendritic cell metabolism. The high expression of CD25 on Treg cells led to 
the proposal that Treg cells act as an ‘IL-2 sink’, depriving effector T cells of this 
cytokine, which they need for proliferation and survival. This has been shown to 
occur in vitro (Pandiyan et al., 2007, Barthlott et al., 2005), but little evidence for this 
phenomenon has been ascertained from in vivo studies and therefore it remains 
controversial (Vignali, 2012). Another mechanism which results in impaired 




are highly expressed on the surface of Treg cells (Kobie et al., 2006, Deaglio et al., 
2007, Borsellino et al., 2007). These enzymes co-operate to convert extracellular 
adenosine tri-phosphate (ATP), which is released through cellular damage, to 
adenosine. Adenosine has been shown to inhibit T cell proliferation through 
interactions with the A2A receptor (A2AR), expressed by these cells. The mechanism 
by which this occurs may involve cyclic AMP (cAMP), a second messenger molecule 
which is increased upon binding of adenosine to A2AR (Ernst et al., 2010), but can 
also be transferred directly from regulatory T cells into conventional T cells through 
gap junctions (Bopp et al., 2007). In naïve T cells cAMP induces expression of 
inducible cAMP early repressor (ICER), which is a repressor at the IL-2 locus (Bopp 
et al., 2007). cAMP can also be transferred directly from Treg cells into dendritic cells 
through gap junctions (Bopp et al., 2007), which has been shown to cause 
downregulation of the co-stimulatory molecules CD80 and CD86 (Fassbender et al., 
2010), hence suppressing naïve T cell activation. 
1.3.2.3 Immunomodulatory mediators 
The key immunosuppressive cytokines secreted by Treg cells are TGFβ and IL-10, 
which also have roles in pTreg cell induction, as previously discussed (Miyara and 
Sakaguchi, 2007). These cytokines act on multiple cell types, including T cells and 
dendritic cells, inhibiting proliferation and activation respectively. Initial in vitro studies 
showed that neither IL-10 nor TGFβ are required for Treg cell mediated suppression 
of conventional T cells (Thornton and Shevach, 1998, Takahashi et al., 1998). 
However, the absence of IL-10, which is particularly important at environmental 
interfaces (Rubtsov et al., 2008), has been shown to impair Treg cell-mediated 




al., 2001, Asseman et al., 1999). There is also evidence from a similar colitis model 
that TGFβ is required for Treg-cell mediated suppression of T cells (Fahlen et al., 
2005). TGFβ exists in a membrane bound, as well as a secretory form, and there is 
in vitro evidence that TGFβ-dependent suppression may be via the membrane bound 
form (Nakamura et al., 2001). The anti-inflammatory cytokine IL-35 can also be 
secreted by Treg cells and has been shown to be required for maximal suppression 
of T cell proliferation in vitro and in vivo (Collison et al., 2007). Interestingly, this 
cytokine can also induce the generation of further IL-35 producing Treg cells from 
naïve T cells (Collison et al., 2010). These FOXP3 negative cells have been shown 
to mediate suppression through IL-35 but not IL-10 or TGFβ. It is clear that there may 
be subsets and mechanisms of suppression which are yet to be discovered, and 
indeed it is emerging that Treg cells release exosomes containing microRNA which, 
upon delivery to effector T cells, can directly suppress proliferation and pro-
inflammatory cytokine expression (Okoye et al., 2014).  
1.3.2.4 Cytolysis/cell cycle arrest 
It has been proposed that Treg cells are able to cause lysis of activated T cells and 
dendritic cells via the perforin-granzyme pathway (Grossman et al., 2004), and 
therefore the suppressive mechanisms utilised by Treg cells include cell death. This 
pathway is more often associated with cytotoxic T cells and natural killer cells, which 
use perforin to create holes in the target cell membrane, facilitating the entry of 
granzymes which induce apoptosis (Dustin and Long, 2010). It has subsequently 
been shown that granzyme B is upregulated in Treg cells upon activation and that 
deficiency of this protease leads to impaired suppression (Gondek et al., 2005, 




suppressive mechanism by Treg cells. These studies also revealed that this is a 
perforin-independent process and therefore it is not currently clear how granzyme B 
is able to enter the target cell, although perforin-independent mechanisms of 
granzyme-mediated cell death have been described (Gross et al., 2003). It has also 
been reported that cell cycle arrest can be induced through the interaction of 
Galectin-1 on Treg cells with CD45/43/7 on naïve T cells (Garin et al., 2007). This 
group showed that blocking of Galectin-1, which is upregulated upon Treg cell 
activation, impairs Treg cell suppression.  
1.3.3 Treg cell homeostasis 
Early in vitro studies indicated that Treg cells are anergic and therefore do not 
proliferate upon TCR stimulation (Takahashi et al., 1998, Itoh et al., 1999, Kuniyasu 
et al., 2000). However, it has since been revealed that Treg cells are a continuously 
activated and highly proliferative T cell subset (Fisson et al., 2003, Walker et al., 
2003a). In vivo cell transfer experiments performed by Fisson et al. (2003) also 
revealed that Treg cells are highly stable, which has since been confirmed by 
multiple research groups (Sakaguchi et al., 2013). It has been reported that if 
transferred into a lymphopoenic environment, a small proportion of Treg cells lose 
expression of FOXP3 (Duarte et al., 2009), however this is not thought to represent 
conversion to conventional T cells as these cells are able to upregulate FOXP3 upon 
encounter with antigen (Miyao et al., 2012). It is also emerging that there may be a 
capacity for memory in this regulatory arm of the immune system. A previous 
publication has shown that foetal antigen specific Treg cells expand in the mother 
during pregnancy, persist after birth, and are able to rapidly accumulate in a 




homeostasis are thought to be delivered via the TCR, CD28 and IL-2Rα. There may 
also be a role for Nrp-1 in supporting Treg cell survival in inflammatory sites. 
1.3.3.1 TCR 
In addition to the requirement for TCR stimulation for Treg cell activation, it has also 
emerged that Treg cell homeostasis is supported by signals through the TCR (Kim et 
al., 2009), and hence encounter with cognate antigen. In accordance with this, Treg 
cells are found to proliferate and accumulate in the lymph nodes in close proximity to 
their target antigen (Walker et al., 2003a, Fisson et al., 2003). Sequencing studies 
have shown that the TCR repertoire varies based on anatomical location (Lathrop et 
al., 2008), again suggesting that Treg cells are enriched in the lymph node nearest 
their antigen, which is thought to strategically position them to maintain tolerance 
(Wheeler et al., 2009). Dendritic cells have been shown to present self-antigens in a 
draining lymph node in non-inflammatory conditions (Scheinecker et al., 2002), and 
therefore may be the source of antigen to support the local homeostatic control of 
Treg cells. Interestingly along with ‘typical’ antigen presenting cells such as dendritic 
cells, macrophages and B cells, various other cells of the immune system have been 
shown to be able to present antigen in various settings and may therefore be termed 
‘atypical’ antigen presenting cells (Kambayashi and Laufer, 2014). This category 
includes Innate Lymphoid Cells (ILCs), which are haematopoietic cells with lymphoid 
morphology but which lack T cell and B cell-receptors, as well as molecules 
expressed by myeloid cells, such as CD11c (Spits and Cupedo, 2012). They can be 
identified by the absence of such markers, as well as expression of Interleukin-7 




1.3.3.1.1 Innate Lymphoid Cells 
ILCs have been categorised into three groups based on the expression of lineage 
defining transcription factors and signature cytokines, of which Group 3 ILCs (ILC3s) 
express the transcription factor RORγ and the cytokines IL-22 and IL-17 (Spits et al., 
2013). ILC3s are primarily found in the gut but also reside in the lymph nodes and 
spleen (Walker et al., 2013). In secondary lymphoid tissue they are located at the 
interface between T and B cell areas, such as the interfollicular regions (Mackley et 
al., 2015). Multiple roles for ILCs within the innate immune system have been 
described, including defence against microbial infections, maintenance of epithelial 
barrier integrity and tissue repair. Further to this, it is becoming apparent that ILCs 
are able to influence the adaptive immune system (Artis and Spits, 2015). 
Interestingly, ILC3s have been shown to process and present antigen in the context 
of MHC II as a mechanism to prevent T cell responses to commensal bacteria in the 
gut (Hepworth et al., 2015, Hepworth et al., 2013). This therefore provides evidence 
that these atypical antigen presenting cells, which do not express CD80/86, have a 
regulatory role in the gut, and it is important to ascertain whether this extends to the 
periphery, where these cells are well placed to interact with recirculating 
lymphocytes. 
 1.3.3.2 CD28 
Initial studies showed that despite the role of CD28 in T cell activation, a model of  
autoimmune diabetes was exacerbated in the absence of this receptor (Salomon et 
al., 2000). The number of Treg cells was markedly decreased in these CD28 




onset. This indicated that CD28 has a role in Treg cell homeostasis, however this is 
challenging to dissect due to the role of CD28 in T cell activation and Treg cell 
development in the thymus (Tang et al., 2003). To overcome these complicating 
factors two models have been generated. The first allows inducible CD28 ablation 
and has revealed that in the absence of CD28, the number of Treg cells in the 
periphery is reduced (Gogishvili et al., 2013). This group demonstrated that this was 
unaffected by removal of the thymus or addition of CD28-sufficient T cells, and 
therefore these data suggest that CD28 is important for Treg cell homeostasis. The 
second model is a mouse in which CD28 selectively depleted from Treg cells, and 
revealed that these mice succumb to severe autoimmune disease, which is 
reversible by addition of CD28-sufficent Treg cells (Zhang et al., 2013). Interestingly, 
this group showed that the number of Treg cells was not affected by the loss of 
CD28. This suggesting instead that the absence of CD28 has a qualitative effect on 
Treg cells, and indeed expression of CTLA-4 was shown to be reduced by 
approximately 50%. In terms of the source of CD28 signaling, it may be that the low 
level of CD80/86 which is expressed on immature dendritic cells in non-inflammatory 
settings serves to maintain Treg cell homeostasis (Bluestone and Abbas, 2003). 
Indeed Bar-On et al. (2011) demonstrated that in mice that lack CD80 and CD86 
expression on CD11c+ dendritic cells, there is a twofold reduction in the number of 
Treg cells in the periphery. 
1.3.3.3 IL-2 
As previously discussed, in vitro experiments have demonstrated that the presence 
of IL-2, as well as TCR stimulation, is necessary for Treg cell activation (Thornton et 




2Rβ deficient mice have shown that IL-2 has a central role in Treg cell homeostasis 
(Fontenot et al., 2005, D'Cruz and Klein, 2005, Malek et al., 2002). Activated T cells 
are the major source of IL-2, which is not produced by Treg cells themselves 
(Almeida et al., 2006). As a result, T cell activation and subsequent IL-2 production 
supports Treg cell activation and survival, ensuring that there is adequate regulation 
of the response. As contraction of the effector response occurs, there is a reduction 
in IL-2 availability and therefore the regulatory response. In support of this theory, 
Almeida et al. (2006) demonstrated that there is a direct relationship between the 
number of Treg cells in the periphery and the number of activated T cells. 
1.3.3.4 Nrp-1 
Signaling through Nrp-1 has been shown to enhance Treg cell stability at 
inflammatory sites in a process dependent on the ligand semaphorin-4a (Delgoffe et 
al., 2013). This group showed that although Nrp-1 is dispensable for Treg cell 
homeostasis, Treg cells lacking this receptor are unable to suppress an anti-tumour 
response. Semaphorin-4a expression by dendritic cells is known to enhance T cell 
activation (Kumanogoh et al., 2002), and this group found that the major cellular 
source of Nrp-1 at the tumour site was dendritic cells. Like Nrp-1, which is a 
semaphorin III receptor, this ligand has also been shown to be important for axonal 
guidance. As such it is enriched in sites such as the eye, where it is expressed by 
retinal epithelial cells (Rice et al., 2004). 
1.3.4 Control of suppression 
Interestingly it has been shown that Treg cells can upregulate transcription factors 




(Koch et al., 2009, Chaudhry et al., 2009, Zheng et al., 2009). For example, Treg 
cells have been shown to upregulate Tbet in response to agonistic anti-CD40, which 
stimulates a strong Th1 response (Koch et al., 2009). Experiments with Tbet-deficient 
Treg cells demonstrated that this transcription factor supports Treg cell homeostasis, 
as well as expression of the chemokine receptor CXCR3, which is postulated to 
direct Treg cell migration towards the site of the Th1 response (Koch et al., 2009). 
Interestingly 40-60% of Treg cells within the colon have been shown to be RORγt+, 
and this population is dependent on the presence of commensal bacteria (Sefik et al., 
2015). Introduction of various species of bacteria back into germ free mice has 
shown that there is not a strong correlation between the bacterial species which 
induce Th17 cells and those which induce RORγt+ Treg cells. Therefore, rather than 
tailoring colonic Treg cells towards Th17 responses, this may be a distinct 
mechanism, which relates to tolerance to commensal bacteria. 
The strength of the immune response is known to influence the magnitude of 
suppression, with high doses of antigen rendering effector T cells resistant to 
suppression (Baecher-Allan et al., 2002, Georger et al., 2003). Interestingly, there 
are multiple reports that during autoimmune disease, rather than there being an 
impairment in regulatory T cell function, conventional T cells become resistant to 
suppression. For example, this has been reported in animal models of type 1 
diabetes (Clough et al., 2008, D'Alise et al., 2008) as well as human studies (Lawson 
et al., 2008, Schneider et al., 2008). High levels of PAMPs, pro-inflammatory 
cytokines and co-stimulatory molecules are thought to contribute to resistance to 
suppression, as detailed below, and therefore this may be a mechanism to restrict 




As an infection is cleared, the antigen load will drop, along with the levels of these 
mediators, which is thought to allow the Treg cells to function to prevent immune 
pathology. This is termed the ‘tuned suppression’ model (Walker, 2009).  
1.3.4.1 Toll-like receptor signaling  
As explored previously, dendritic cells become activated in response to signaling 
through their PRRs, which include the family of Toll-like receptors. Upon activation, 
dendritic cells produce pro-inflammatory cytokines such as IL-6. This cytokine has 
been shown to partially hinder suppression by Treg cells (Pasare and Medzhitov, 
2003, Iwasaki and Medzhitov, 2004) therefore, TLR stimulation may indirectly affect 
Treg cell activity. Interestingly, various TLRs are also expressed by conventional and 
regulatory T cells and signaling through TLR9, which recognises bacterial or viral 
DNA, has been shown to directly release effector T cells from Treg cell mediated 
suppression (LaRosa et al., 2007). Similarly, signaling through TLR2 and TLR8, 
which are constitutively expressed by Treg cells, impairs suppression (Peng et al., 
2005, Sutmuller et al., 2006). These TLRs recognise bacterial lipoproteins and viral 
single stranded RNA respectively. In contrast, signalling through TLR5, which 
recognises bacterial flagellin, enhances Treg cell function (Crellin et al., 2005). 
Therefore, bacterial and viral PAMPS have the ability to reduce suppression via 
interactions with PRRs expressed by antigen presenting cells, as well as 
conventional and regulatory T cells, with one exception noted.  
1.3.4.2 Cytokines 
Multiple pro-inflammatory cytokines have been shown to contribute to resistance to 




and IL-21 (Attridge and Walker, 2014). It has been suggested that these cytokines 
release T cells from their dependence on CD28 signals, a feature which is exploited 
by Treg cells (Attridge and Walker, 2014). As previously discussed, Treg cells 
constitutively express CTLA-4, which interferes with signalling between CD28 and its 
ligands CD80/86. Therefore, releasing T cells from their dependence on CD28 
signals would deprive Treg cells of a key mechanism of suppression. Alternatively, 
these cytokines may indirectly affect suppression by interfering with Treg cell 
homeostasis. Attridge et al. (2012) demonstrated that IL-21 can reduce IL-2 
production by T cells and that although Treg cells are critically dependent on IL-2, 
effector T cell proliferation can be supported by IL-21. Therefore, this cytokine can 
remove survival signals from Treg cells without adversely affecting effector T cell 
homeostasis. 
1.3.4.3 TNF receptors 
Interactions between TNF receptors and their ligands have also been shown to 
influence suppression. This family is known to contribute to a wide range of 
processes within immune system via regulation of cell apoptosis, survival, 
proliferation and differentiation (Aggarwal et al., 2012). TNF receptors are transiently 
expressed on T cells during activation, where they act as co-stimulatory molecules, 
and various TNF receptors are constitutively expressed by Treg cells (Croft, 2009). 
Interactions between the TNF receptor GITR and its ligand have been shown to 
reduce suppression via effects on conventional rather than regulatory cells (Stephens 
et al., 2004). It has also been reported that that interactions between OX40 and its 




OX40 on Treg cells is controversial within the literature and there is also evidence 
that OX40 and IL-2 signal co-operatively to support Treg cells (Xiao et al., 2012).  
1.3.5 Therapeutic avenues 
There are many situations in which boosting Treg cell activation, survival or function 
would be beneficial, such as autoimmune disease, allergy and transplantation. 
Indeed, proposed approaches for the treatment of autoimmune disease include in 
vivo or ex vivo Treg cell expansion, as well as enhancement of suppressive ability 
(Miyara et al., 2014). Conversely, because many tumours contain high numbers of 
Treg cells which are able to suppress the anti-tumour response (Nishikawa and 
Sakaguchi, 2010), inhibition of Treg cells would aid clearance by the immune system. 
Current advances in anti-tumour immunotherapy have included strategies to release 
effector T cells from regulation, for example by blocking CTLA-4 and Programmed 
Death-1 (PD-1), which is another negative regulator of T cell activation expressed by 
T cells (Curran et al., 2010). Interestingly there are reports that anti-CTLA4 treatment 
can cause Treg cell depletion in certain contexts (Selby et al., 2013, Simpson et al., 
2013). An ideal therapeutic would boost the effector response whilst inhibiting Treg 
cells. It is clear that the ability to manipulate the activation, survival or function of 
Treg cells would have far reaching implications, either tipping the balance in favour of 
the effector or regulatory T cells. 
1.4 Aims of the study 
 Establish a method to study Treg cell survival and function in vivo. 
 Investigate the sources of cellular support, and the role of TNF receptors in 


























2.1 Mice  
Animals were bred in accordance with Home Office Guidelines at the  
. C57BL/6 mice were used as wildtype controls 
in all experiments using adult mice. In embryonic spleen experiments BALB/c 
embryos were used due to availability. Mice were age matched when possible, and 
all genetically modified strains were compared to wildtype mice which had been bred 
in-house. External wildtype mice, from Harlan or Charles River, were utilised in all 
other circumstances. All manipulated mice strains were on a C57BL/6 background 
and are described in Table 2.1. Mice were used at 6-12 weeks of age and were 
sacrificed by a rising concentration of CO2.  
Strain Phenotype Source 
FOXP3GFP Regulatory T cells identified by GFP expression. (Bettelli et al., 2006) 
RORγt KO 
Mice lack lymph nodes, Th17 cells, 
RORγt+ ILCs, and exhibit altered 
thymocyte development.  
Ivanov et al., 2006 
FOXP3GFP x 
RORγt KO 
Mice lack lymph nodes, Th17 cells, 
RORγt+ ILCs, and exhibit altered 
thymocyte development. Regulatory 
T cells identified by GFP expression 
Cross performed by 
Dr Fiona McConnell, 
unpublished  
OX40/CD30 dKO 
T cells lack the co-stimulatory 
receptors OX40 and CD30, affecting 
T cell activation. 
Gaspal et al., 2005 
OX40 KO 
T cells lack the co-stimulatory 
receptor OX40, affecting T cell 
activation. 
Kopf et al., 1999 
Table 2.1: Genetically modified mouse strains  
2.2 Solutions 
Gey’s solution was used to remove red blood cells from spleen cell suspensions (5 




and 70 ml of distilled H2O (Table 2.2). Each solution was made up to 1 L with distilled 
H20 and autoclaved. The composition of other solutions used is shown in Table 2.3.  
Solution Composition 
A 
35 g    NH4Cl 
1.85 g    KCl 
1.5 g    Na2HPO4.12H2O 
0.119 g  KH2PO4 
5 g    Glucose 
25 g    Gelatin 
1.5 ml    1% Phenol red 
B 
4.2 g    MgCl2.6H2O 
1.4 g    MgSO4.7H2O 
3.4 g    CaCl2 
C 22.5 g    NaHCO5 
Table 2.2: Composition of Gey’s solution 
Solution Composition 
RPMI Complete RPMI 1640 (Gibco) 
RPMI + EDTA Complete RPMI 1640 (Gibco) supplemented with 2.5 mM 
EDTA (Fluka Analytical) 
Culture Medium 
Complete RPMI 1640 (Gibco) supplemented with 2% 
foetal bovine serum (Biosera or Invitrogen), 2 mM L-
glutamine (Sigma) and 1% penicillin and streptomycin 
(Gibco) 
PBS Dulbecco’s phosphate buffered saline +MgCl2 +CaCl2 (Gibco) 
Flow cytometry 
staining buffer 
Dulbecco’s phosphate buffered saline +MgCl2 +CaCl2 
(Gibco) supplemented with 2% foetal bovine serum 




Phosphate buffered saline (Sigma) supplemented with 
1% bovine serum albumin (Sigma). 




2.3 Tissue dissection and cell isolation 
For T cell isolation, the thymus or spleen +/- a pool of lymph nodes, were harvested 
from mice and placed in 3 ml RPMI + EDTA. The pool of lymph nodes included: 
cervical, brachial, auxiliary, inguinal and mesenteric. Fat was cleaned off the tissues 
using forceps under a dissection microscope. Tissues were crushed through a 70 µm 
cell strainer (Falcon) using RPMI + EDTA to wash. After centrifuging at 4°C for 6 
minutes at 394 relative centrifugal force (rcf), red blood cell lysis was performed 
(spleen or spleen and lymph node suspensions only). To lyse red blood cells 5 ml 
Gey’s solution was added to the cell pellet, the suspension was mixed and incubated 
on ice for 5 minutes. Cells were washed in 10 ml RPMI + EDTA to prevent further cell 
lysis. As with all washes, cells were centrifuged for 6 minutes at 394 rcf. Cells were 
re-suspended in Flow Cytometry Staining Buffer (SB) and filtered through a 70 µm 
cell strainer (Falcon). 
For Innate Lymphoid Cell isolation, spleen and inguinal and mesenteric lymph nodes 
were harvested from mice, placed in 3 ml RPMI, and fat was removed. The lymph 
nodes were teased apart with forceps and the spleens cut up using scissors. For 
digestion 7.5 µl DNase I (10 mg/ml stock, Sigma) and 7.5 µl collagenase/ dispase 
(100 mg/ml stock, Roche Diagnostics) were added and tissues were incubated at 
37°C for 20 minutes. To stop digestion, 60 µl 0.5 M EDTA (Fluka Analytical) was 
added. Cells were crushed through a 70 µl cell strainer (Falcon) and red blood cell 
lysis was performed on spleen samples as previously described. All samples were 





2.4 Embryonic spleen culture 
Embryonic spleens were dissected from BALB/c embryos at day 15 of gestation. A 
maximum of six spleens were placed on a sterile 0.8 µm nucleopore filter (Millipore) 
laid on a 1 cm2 piece of sterile antiwrap sponge. Each sponge-filter pair was placed 
in 4ml Culture medium containing 100 ng/ml IL-7 (Peprotech) in a 90 mm petri dish 
(Sterilin). These were placed in sterile humidified chambers and incubated for 7 days 
at 37°C. Embryonic spleens were removed from the filters, placed in groups of six, 
and teased apart with forceps. Cells were crushed through a 70 µm cell strainer 
(Falcon) and re-suspended in 1 ml culture medium. Cells were cultured overnight 
with 100 ng/ml IL-7 +/- 100 ng/ml TL1A (R&D Systems) (Kim et al., 2006) or 10 μg/ml 
agonistic anti-DR3 (Biolegend). The following day cells were washed twice in PBS 
and incubated for 15 minutes at 4°C with Livedead® fixable near-IR dead cell stain 
kit (Life Technologies, 1/2000). Cells were then washed again in PBS before addition 
of antibodies. 
2.5 Identification of antigen-specific T cells 
Cells from secondary lymphoid tissue were incubated with MHC class II tetramers to 
detect specific T cell populations. These consist of four biotinylated peptide-MHC 
class II molecules attached to a fluorescently conjugated streptavidin core. Tetramers 
were obtained from the National Institute of Health Tetramer Facility or generated by 
the Protein Expression Facility at the University of Birmingham. To detect 2W1S-
specific T cells, 2W1S: I-Ab MHC class II tetramers conjugated to PE or APC were 
utilised. To detect LLO190-201-specific T cells LLO: I-Ab MHC class II tetramers 




invariant chain peptide were used to exclude non-specific tetramer binding during the 
gating strategy. Cells were incubated with 9.3 µg/ml MHC class II tetramers at room 
temperature (water bath) in the dark for 1hr, and agitated every 15 minutes. Where 
there was a high frequency of 2W1S+-specific T cells, half of the total sample was 
incubated with tetramers.  
Where there was a low frequency of 2W1S+- specific T cells, all isolated cells were 
incubated for 15 minutes at 4°C with magnetic anti-PE or anti-APC microbeads (1:10, 
Miltenyi Biotech), and positive selection was performed as described by Moon et al. 
(2009). This was achieved by passing cell suspensions through MACS separation 
columns held on a magnet (Miltenyi Biotech). The columns were washed 3 times with 
3 ml SB and the enriched fraction was collected by removing the columns from the 
magnet and flushing using 5 ml SB. To identify 2W1S-specific T cells in naïve mice, 
the enriched fraction from two FOXP3GFP mice were pooled prior to addition of 
antibodies in order to increase the number of antigen-specific Treg cells. 
2.6 Immunisation 
All injections were carried out in 200 µl sterile PBS. When multiple immunisations 
took place they were performed 7 days apart and mice were sacrificed 7 days after 
the final injection. Mice were injected intravenously with 50 or 100 µg 2W1S peptide 
(>70% purity, Proimmune). For anti-DR3 injections, mice were injected intravenously 
with 10µg agonistic anti-TNFRSF25 (DR3) monoclonal antibody (Biolegend) 2W1S 
peptide, or separately by intraperitoneal injection. To measure IFNγ production an in 
vivo peptide re-stimulation was performed (Rowe et al., 2012). Mice were immunised 




4 hours later. To block cytokine release, and hence facilitate detection of IFNγ, 10 µg 
Brefeldin A (Sigma, B6542-5MG) was added during incubation at room temperature 
with MHC class II tetramers.  
ActA deficient Listeria monocytogenes-expressing 2W1S peptide (a kind gift from Dr 
Marc Jenkins) was grown overnight at 37°C on plates containing Lennox Luria-
Bertani broth with agar (Sigma Aldrich) supplemented with 20 µg/ml chloramphenicol. 
A single colony was then cultured overnight in Luria-Bertani broth supplemented with 
20 µg/ml chloramphenicol at 37°C in a shaking incubator. Bacteria were diluted in 
Luria-Bertani broth and cultured with 20 µg/ml Chloramphenicol at 37°C in a shaking 
incubator until an optical density (OD600) of over 0.1 was reached, as determined 
using a Spectrophotometer (Jenway). Bacteria were washed twice and re-suspended 
in sterile PBS such that the OD600 was 0.1 and therefore equal to 108 bacteria/ml. 107 
bacteria were subsequently injected intravenously into each mouse. 
Administration of IL-2/anti-IL-2 complexes was used to stimulate proliferation of 
Innate Lymphoid Cells (Van Gool et al., 2014). Prior to injection, IL-2 (1 µg per 
mouse, Peprotech) and anti-IL-2 (5 µg per mouse, Bio Legend JES6-1A12), were 
incubated in 200 µl PBS for 30 minutes at 37°C. Complexes were diluted in PBS 
immediately prior to intraperitoneal injection such that each mouse was given 1 µg IL-
2 complexed with 5 µg anti-IL-2 in 200 µl PBS. Complexes were administered daily 






2.7 Flow Cytometry 
Cells were incubated with antibodies at 4°C for 30 minutes in 50µl Staining Buffer 
(SB) in a 96 U bottomed plate. After incubation with antibodies directed to cell 
surface antigens, cells were washed twice in 200 µl SB. As for all washes, plates 
were centrifuged at 4°C for 3 minutes at 394 rcf. Cells were fixed and permeabilised 
using a FOXP3 staining buffer kit (eBioscience). As described in the manufacturer’s 
instructions, cells were incubated with 100 µl fixation/permeabilisation solution (1-part 
concentrate to 3-parts diluent) at 4°C for 30 minutes, before being washed with 
permeabilisation buffer (diluted to 1x with distilled H20). Cells were incubated with 
antibodies directed against intracellular antigens in 50 µl of permeabilisation buffer at 
4°C for 30 minutes. Cells were then washed in 200 µl permeabilisation buffer, 
followed by 200 µl SB. Cells were re-suspended in 250 µl SB and transferred to 
polystyrene fluorescence-activated cell sorting tubes (Becton). To facilitate cell 
quantification, 10000 Accucount blank particles (Spherotech) were added to each 
sample. Forward and side scatter were used to exclude dead cells and 2-3 million 
events were acquired per sample. Cell suspensions which had each been incubated 
with antibodies conjugated to one of the fluorochromes used were acquired prior to 
the samples and used set up the compensation parameters. Isotype controls were 
used to set the lower threshold for expression of a particular marker. Samples were 
acquired using an LSR Fortessa X-20 or LSR II, running FACS Diva software (BD 
Biosciences). FlowJo software (Tree Star) was then used to analyse the data. 








Dilution Clone Manufacturer 
Primary antibodies 
B220 
Pacific Blue 1/200 
RA36B2 
eBioscience 
FITC 1/300 eBioscience 
CCR6 BV 421 1/50 29-2L17 BioLegend 
CD11b Pacific Blue 1/200 MI/70 eBioscience 
CD11c 
Pacific Blue 1/200 
N418 
eBioscience 
FITC 1/300 eBioscience 
CD3 
A700 1/100 500A2 eBioscience 





BV 605 1/800 BioLegend 
BV 785 1/300 BioLegend 





V500 1/200 BioLegend 
CD25 
APC 1/500 PC61 BD Biosciences 
BV 650 1/200 UC10-4B9 BioLegend 
CD39 APC 1/100 Duha59 BioLegend 
CD44 
PerCP Cy5.5 1/300 
IM7 
eBioscience 
A700 1/100 eBioscience 
PE Cy7 1/800 eBioscience 
CD45.1 PE 1/200 A20 eBioscience 
CD73 PerCP Cy5.5 1/200 TY/11.8 BioLegend 
DR3 PE 1/100 4C12 BioLegend 
I-Ab (MHC II) BV 510 1/500 M5/114.15.2 BioLegend 
I-Ad (MHC II) FITC 1/800 39-10-8 BioLegend 
IFNγ PE-Cy7 1/200 XMG1.2 eBioscience 
IL-7Rα PE Cy7 1/100 A7R34 eBioscience 




Ki67 PE-Cy7 1/400 SolA15 eBioscience 
Ly6c BV 711 1/500 HK1.4 BioLegend 
Neuropilin-1 
(goat) 
Unconjugated 1/200 AF566 R&D Systems 
NKp46 BV 605 1/200 29A1.4 BioLegend 
OX40L PE 1/50 RMB4L eBioscience 




AF647 1/800 A21447 Invitrogen 




Dilution Clone Manufacturer 
CD3 A700 1/100 500A2 eBioscience 





PE 1/100 eBioscience 
GATA-3 PerCP 710 1/50 TWAJ eBioscience 





Table 2.5: Antibodies used for identification of intracellular antigens 
2.8 Immunofluorescence and Image Analysis 
Mesenteric lymph nodes were frozen in Optimal Cutting Temperature compound 
(Tissue-Tek) on dry ice and stored at -80°C. 6 µm sections of frozen tissue were 
mounted on 4 spot slides (Hendley-Essex) prior to immunofluorescence. Sections 




After being air dried for a further 30 minutes, slides were stored at -20°C. When 
required, slides were air dried for 30 minutes and hydrated in PBS for 5 minutes. 
They were blocked with 10% horse serum in Immunofluorescence Staining Solution 
(SS) for 15 minutes to prevent non-specific binding of antibodies. Following removal 
of blocking solution, primary antibodies were diluted in SS and added to sections for 
20 minutes. After washing for 5 minutes in PBS, further application of antibodies, 
interspersed with washing was carried out. Each subsequent antibody was cross 
absorbed with 10% mouse serum in 100 µl SS for 30 minutes on ice before being 
diluted to the appropriate concentration. Antibodies and reagents used for 
immunofluorescence staining are listed in Table 2.6.  
 Step Conjugate  Dilution Clone Manufacturer 
Primary 
RORt (rat) - 1/30 Poly6362 Bio Legend 
CD3 Biotin 1/100 S11A2 eBioscience 
MHC II AF647 1/150 AF6-120.1 Bio Legend 
Neuropilin-1 (goat) Unconjugated 1/200 AF566 R&D Systems 
Secondary 





AF647 1/800 A21447 Invitrogen 
Quaternary 




AF488 1/200 - 
Life 
Technologies 
Streptavidin AF555 1/500 - Invitrogen 




Sections were then washed, and incubated in DAPI (4’,6-diamidino-2-phenylindole) 
solution for 20 seconds. Sections were then washed three times in PBS, before 
mounting using ProLong Gold Antifade reagent (Invitrogen). Coverslips were placed 
on top of each slide, sealed with clear nail varnish and air dried overnight. Analysis 
was performed using a LSM510 confocal microscope or LSM780 Zen microscope 
(Zeiss) and images were viewed using LSM Image Browser (Zeiss).  
2.9 Statistical Analysis & Graphs 
All graphs presented within this study were created using Prism 4 software. Statistical 
significance was tested using the Mann–Whitney U test (non-parametric), and a two 
tailed p value was calculated. P values < 0.05 were considered significant. Median 














3.0 DEVELOPMENT OF A MODEL TO STUDY 














Although a wealth of knowledge has been built up about Treg cells, there has been 
some disparity in findings between in vitro and in vivo experiments (Vignali, 2012). 
The most fundamental example of this is that in vitro, Treg cells were shown to be 
rendered anergic upon TCR stimulation (Takahashi et al., 1998, Itoh et al., 1999, 
Kuniyasu et al., 2000), whereas the majority of data from in vivo experiments reveals 
that these cells are in fact highly proliferative and continuously activated (Fisson et 
al., 2003, Walker et al., 2003a). In addition, there are concerns that strong 
conclusions have been made about the range of suppressive mechanisms deployed 
by Treg cells without sufficient evidence (Vignali, 2012). For example, the evidence 
that Treg cells act as an ‘IL-2 sink’ all comes from in vitro experiments. There have 
also been occasions of false negatives arising from in vitro work, for example little IL-
10 and TGFβ can be identified in vitro, and blocking these cytokines has little effect 
(Miyara and Sakaguchi, 2007), but a clear role for these immunosuppressive 
cytokines has been revealed in vivo (Miyara and Sakaguchi, 2007). This study 
therefore aims to investigate Treg cell survival and function in vivo. 
In this study antigen-specific Treg cells have been assessed to aid clarification of 
specific effects on survival versus function, since the precise time of expansion can 
be controlled. Although it is technically challenging to study Treg cell function in vivo, 
an approach which successfully achieves this in an antigen-specific manner has 
recently been described (Rowe et al., 2012). Here Treg cells were expanded to 
approximately 50% of the antigen-specific population, and the effect on a subsequent 
response was measured. The principles from this suppression assay will therefore be 




One widely used method to study T cells in an antigen-specific manner is the use of 
TCR-transgenic mice, which have many benefits, such as the potential to transfer 
and track large numbers of T cells. However it has been reported that there is an 
inverse relationship between the size of a clonal population and their survival (Hataye 
et al., 2006), therefore cell survival may be adversely affected. In addition, TCR 
transgenic mice on a T cell deficient background (RAG KO), which are ideal for 
isolating cells for transfer, lack Treg cells due to the importance of antigen in Treg 
cell selection in the thymus (Walker et al., 2003b, Itoh et al., 1999). Rather, I sought 
to develop a strategy where an endogenous polyclonal population could be tracked, 
using approaches pioneered by Marc Jenkins (Moon et al., 2007, Rees et al., 1999).  
The Jenkins lab have demonstrated that an endogenous naïve T cell population is 
expanded upon encounter with 2W1S peptide, a variant of peptide 52-68 of the I-E 
alpha chain (Rudensky et al., 1991). The number of naïve T cells which are specific 
to this antigen is relatively large, at approximately 200 cells per mouse (Moon et al., 
2007). In contrast, two other potential model antigens, peptide 427-441 from the FLiC 
protein of Salmonella typhimurium and peptide 323-339 from chicken ovalbumin 
each have a naïve T cell pool of approximately 20 cells per mouse (Moon et al., 
2007). This is important as it has been found that within the primary response CD4+ T 
cell populations expand in proportion to their naïve T cell frequency (Moon et al., 
2007). It is also possible to track naïve 2W1S+ Treg cells whereas this would be 
almost impossible for OVA and FLiC specific endogenous populations. To identify 
these antigen-specific T cells, fluorochrome conjugated MHC class II tetramers can 
be used (Moon et al., 2007). The presence of the fluorochrome enables enrichment 




detection by flow cytometry (Moon et al., 2009). Enrichment is particularly important 
when identifying a small subset of responding T cells. Therefore, in this study, this 
antigen-specific approach will be optimised for the study of Treg cells. Further to this 
an assay will be developed to study Treg cell function in vivo, based on work by 
Rowe et al. (2012). 
The 2W1S peptide can also be provided through infection with ActA-deficient Listeria 
monocytogenes-expressing 2W1S (Lm-2W1S) (Ertelt et al., 2009). This approach 
enables the study of Treg cells within the context of an infection, which is important 
since the nature and strength of an immune response is known to influence the 
magnitude of suppression (Miyara and Sakaguchi, 2007). Listeria monocytogenes is 
a gram positive intracellular bacteria, which is able to survive within macrophages 
after phagocytosis, but also can invade most cell types (Portnoy et al., 2002). Figure 
3.1 provides a representation of the life cycle of this bacterium, with the role of ActA 
shown. To gain entry to non-phagocytic cells, the bacterial surface proteins Internalin 
A (InlA) and Internalin B (InlB) interact with cell surface receptors E-Cadherin and 
Met to trigger receptor mediated internalisation (Mengaud et al., 1996, Shen et al., 
2000). Once inside the cell, the bacterium is able to escape into the cytosol through 
the action of the haemolysin listeriolysin-O (LLO), as well as two phospholipase C 
enzymes (Vázquez-Boland et al., 2001). Once in the cytoplasm the bacterium 
replicates and is able to spread to other cells through the action of bacterial actin 
assembly-inducing (ActA) protein. This protein mediates reorganisation of the actin 
cytoskeleton, to form “Comet tails” which allow the bacterium to move into 
neighbouring cells via plasma membrane protrusions (Tilney and Portnoy, 1989). As 




protein prevents the spread of this bacterium, facilitating its clearance by the immune 
system. Infection with ActA-deficient Listeria monocytogenes-expressing 2W1S 
therefore results in a sub-clinical acute infection, which is cleared within five days 
(Goossens and Milon, 1992). Replication of this bacterium primarily occurs in 
macrophages, which secrete TNFα and IL-12 in response to infection. This 
stimulates IFNγ production by NK cells, which increases the bactericidal activity of 
macrophages and is thought to be the key cytokine in controlling listeria 









Figure 3.1: Life-cycle of Listeria monocytogenes. The bacterium (red) enters 
macrophages through phagocytosis, or uses Internalin A (InlA) and Internalin B (InlB) 
to gain entry to non-phagocytic cells. Escape from the vacuole is mediated by the 
haemolysin listeriolysin-O (LLO), and two phospholipase C (PLC) enzymes produced 
by the bacterium (PI-PLC and PC-PLC). Once in the cytosol, the bacterium replicates 
and travels along the actin cytoskeleton in an ActA dependent process involving the 
formation of “comet tails”. This allows spreading to adjacent cells within which the 
bacterium is once again able to escape the vacuole, which has a double membrane. 
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Expanding antigen-specific regulatory T cells  
To first identify 2W1S+ T cells, wildtype (WT) mice were immunised with 100 µg 
2W1S peptide or PBS as a control. In previous publications between 50-125 µg 
2W1S peptide have been used to expand 2W1S+ T cells (Ertelt et al., 2009, Moon et 
al., 2007), therefore a concentration within this range was used. Seven days after 
immunisation, the spleen and a pool of peripheral lymph nodes were harvested from 
mice and tetramer staining and enrichment was performed. The gating strategy is 
shown in Figure 3.2a, in which T cells are identified by CD3 and CD4 expression, as 
well as the absence of B cell and myeloid cell markers B220, CD11b and CD11c. In 
PBS immunised mice (naïve) there is a small population of CD44lo 2W1S+ T cells, 
which is expanded upon immunisation with 2W1S peptide (Figure 3.2b, c). These 
2W1S+ T cells express the activation marker CD44, indicating that these cells have 
been activated in response to immunisation. To control for non-specific tetramer 
binding, cells from 2W1S peptide-immunised mice were stained with MHC class II 
tetramers loaded with MHC class II-associated invariant chain peptide (CLIP) (Figure 
3.2d). During antigen processing CLIP is transiently held in the peptide groove, 













































Figure 3.2: Identification of 2W1S-specific T cells. (A) Gating strategy for 
CD4 T cells: CD3+CD4+B220−CD11b−CD11c−. (B) Identification of 2W1S: I-Ab+ T 
cells in WT mice immunised intravenously with PBS (left) or 2W1S peptide 
(middle and right). After 7 days, a pool of lymph nodes and spleen were 
analysed. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. Either 
control (CLIP: I-Ab) or 2W1S: I-Ab tetramers were used. Plots are representative 





To assess generation/expansion of 2W1S+ Treg cells, WT mice were immunised with 
50 µg 2W1S peptide or infected with 107 Lm-2W1S. After 7 days the spleen and a 
pool of peripheral lymph nodes were harvested from these mice and enriched for 
2W1S-specific T cells. Treg cells were identified within the 2W1S+ T cell population 
by expression of the transcription factor FOXP3. Consistent with previous reports 
(Ertelt et al., 2009), Lm-2W1S induced a robust 2W1S+ T cell response, with a large 
number of conventional 2W1S+ T (Tconv) cells (median 4455) (Figure 3.3a, b), but a 
low number of Treg cells (median 59) (Figure 3.3c) Following administration of 
2W1S peptide, fewer 2W1S+ Tconv cells were expanded, but the number of Treg 
cells was similar (median 69 and median 79 respectively) (Figure 3.3d). As a result, 
there was a greater proportion of regulatory to conventional 2W1S+ T cells than 
observed after Lm-2W1S administration (median 13.2% vs median 1.2%) (Figure 
3.3e). Although Treg cell numbers are similar between the two approaches, 
administration of 2W1S peptide induces a greater proportion of 2W1S+ Treg cells 













































































  Figure 3.3: 2W1S+ regulatory T cells can be expanded to 10% of the 
population by 2W1S peptide but not Lm-2W1S. WT mice were infected 
intravenously with ActA deficient Listeria monocytogenes-expressing 2W1S 
peptide (Lm-2W1S), or were immunised with 2W1S peptide intravenously. After 7 
days, a pool of lymph nodes and spleen were analysed. (A) Identification of 
FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells after either treatment. Plots are 
pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- 
and FOXP3+ CD44hi2W1S: I-Ab+ T cells after infection with Lm-2W1S. (C) 
Percentage of FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells after infection with 
Lm-2W1S. (D) Enumeration of FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells 
after immunisation with 2W1S peptide. (E) Percentage of FOXP3- and FOXP3+ 
CD44hi2W1S: I-Ab+ T cells after immunisation with 2W1S peptide. (B-E) Bars 
show medians. Mann–Whitney test, ***p < 0.001.  At least 10 samples per group 




Investigating methods to increase 2W1S+ Treg cell numbers 
Although 2W1S peptide can be used to expand Treg cells, the number detected was 
very low, which may limit survival experiments. To enhance the ability to detect 
2W1S+ Treg cells over time, tools for enhancing the total number of cells were 
explored. An agonistic anti-Death Receptor 3 (DR3) antibody (4C12) has previously 
been shown in mice to selectively increase the percentage of CD4+ T cells which are 
FOXP3+ in the blood to 30-35% (Schreiber et al., 2010). This antibody signals via the 
Tumour Necrosis Factor receptor DR3, which is expressed primarily on T cells, 
including Treg cells, and is thought to expand existing Treg cells by increasing their 
efficacy for IL-2 (Schreiber et al., 2010). To investigate whether agonistic anti-DR3 
can be used to selectively boost Treg cells within the 2W1S+ T cell population, WT 
mice were injected with 10 µg agonistic anti-DR3 antibody and 50 µg 2W1S peptide. 
2W1S+ Treg cells were then enumerated at day 7 and compared with mice 
administered 50 µg 2W1S peptide alone. This concentration of agonistic anti-DR3 
was administered because it has been demonstrated to elicit maximal expansion of 
Treg cells (Schreiber et al., 2010). Again the spleen and a pool of peripheral lymph 
nodes were harvested from these mice and enriched for 2W1S-specific T cells. 
Upon agonistic anti-DR3 administration, a 2.5-fold increase in the overall Treg cell 
percentage was observed (median 12.8% vs median 29.8%) (Figure 3.4a, b). This 
was therefore similar to the effect observed by Schreiber et al. (2010). However, both 
the regulatory and conventional 2W1S+ T cell populations were found to be 
increased, and as a result the percentage of 2W1S+ Treg cells remained at 
approximately 10% (Figure 3.4c). The number of 2W1S+ Tconv cell numbers 




of 2W1S+ Treg cells increased by 9.3-fold (median 79 vs median 739) (Figure 3.4e). 
Therefore, administration of agonistic anti-DR3 increased both the number of 
regulatory and conventional 2W1S+ T cells to a similar degree, rather than eliciting a 
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Figure 3.4: Agonistic anti-DR3 can boost 2W1S+ regulatory T cell numbers. 
WT mice were immunised intravenously with 2W1S peptide +/- agonistic anti-DR3 
antibody. After 7 days, a pool of lymph nodes and spleen were analysed. (A) 
Identification of FOXP3+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Percentage of T cells which are 
FOXP3+ (Treg cells). (C) Identification of FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ 
T cells. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (D) 
Enumeration of FOXP3-CD44hi2W1S: I-Ab+ T cells (Tconv cells) (E) Enumeration 
of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). (B, D, E) Bars show medians. 
Mann–Whitney test, ***p < 0.001.  At least 10 samples per group were pooled 
from two independent experiments. Tconv = conventional T cells, Treg = 




To further understand the effects of agonistic anti-DR3, the expression of DR3 on 
2W1S+ T cells was characterized. To expand 2W1S+ T cells, WT mice were 
immunised with 100 µg 2W1S peptide. The spleen and a pool of peripheral lymph 
nodes were harvested 7 days later and enriched for 2W1S-specific T cells. The DR3 
antibody was validated using cells isolated from DR3 KO mice (Figure 3.5a). The 
number of DR3+ 2W1S+ Treg cells found to express DR3 was 2.0-fold greater than 
the number of DR3+ 2W1S+ Tconv cells (median 63.2% vs median 31.2%) (Figure 
3.5b, c). Similarly, significantly more regulatory than conventional T cells were shown 
to express DR3 in the overall T cell population (median 72.3% vs median 47.4%) 
(Figure 3.5d, e). As both conventional and regulatory 2W1S+ T cells express DR3, it 







Figure 3.5: DR3 is expressed on 60% of 2W1S+ regulatory T cells. (A) 
Validation of anti-DR3 antibody on FOXP3+ cells from the mesenteric lymph node 
of WT and DR3 KO mice. Plots are representative of at least three mice. (B) WT 
mice were immunised intravenously with 2W1S peptide and a pool of lymph 
nodes and spleen were analysed 7 days later. Identification of DR3 on FOXP3- 
and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (C) Percentage of DR3+ FOXP3- and 
FOXP3+ CD44hi2W1S: I-Ab+ T cells. (D) Identification of DR3 on FOXP3- and 
FOXP3+ T cells. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (E) 
Percentage of DR3+ FOXP3- and FOXP3+ T cells. (C, E) Bars show medians. 





























































Repeated exposure to an antigen has been show to boost Treg cell numbers, and 
therefore it has been proposed that repeated administration of an autoantigen could 
be used to induce tolerance in autoimmune disease (Sabatos-Peyton et al., 2010). 
To determine whether repeated administration of 2W1S peptide and agonistic anti-
DR3 can affect the proportions of regulatory and conventional 2W1S+ T cells, WT 
mice were immunised once or twice with 50 µg 2W1S peptide +/- 10 µg agonistic 
anti-DR3. Seven days after their final injection, the spleen and a pool of peripheral 
lymph nodes were harvested and tetramer staining and enrichment was performed. 
After two immunisations of 2W1S peptide +/- agonistic anti-DR3 the regulatory T cells 
within the 2W1S+ T cell population were indeed boosted (Figure 3.6a). The 
percentage of Treg cells increased by 1.6-fold following two immunisations of 2W1S 
peptide (median 13.2% vs median 21.4%) (Figure 3.6b) and by 1.7-fold following two 
immunisations of 2W1S peptide and agonistic anti-DR3 (median 9.3% vs median 
16.0%) (Figure 3.6c). In the mice administered 2W1S peptide, this increase in 
percentage was also associated with a significant increase in regulatory but not 
conventional 2W1S+ T cell number (Figure 3.6d, e). However, in the mice given 
2W1S peptide and agonistic anti-DR3 this increase in percentage did not translate to 
a significant increase in the number of 2W1S+ Treg cells (Figure 3.6d, e). There was 
considerable variation in the percentage after two injections; however, this protocol 
clearly has the potential to boost the percentage of Treg cells within the 2W1S+ T cell 
population. Therefore, to expand the highest number of 2W1S+ Treg cells, and to 
increase their percentage, two immunisations of 2W1S peptide and agonistic anti-
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  Figure 3.6: Multiple immunisation can boost the percentage of 2W1S+ 
regulatory T cells. WT mice were immunised intravenously with 2W1S peptide 
+/- agonistic anti-DR3 antibody and this was repeated after 7 days. After another 
7 days a pool of lymph nodes and spleen were analysed. (A) Identification of 
FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Percentage of FOXP3+CD44hi2W1S: I-
Ab+ T cells (Treg cells) after immunisation with 2W1S peptide. (C) Percentage of 
FOXP3+CD44hi2W1S: I-Ab+ T cells (Treg cells) after immunisation with 2W1S 
peptide and agonistic anti-DR3. (D) Enumeration of FOXP3-CD44hi2W1S: I-Ab+ T 
cells (Tconv cells). (E) Enumeration of FOXP3+CD44hi2W1S: I-Ab+ T cells (Treg 
cells). (B, C) Bars show medians. Mann–Whitney test, *p < 0.05, **p < 0.01. At 
least 10 samples per group were pooled from two independent experiments. (D, 
E) Means ± SEM are shown. Mann–Whitney test, *p < 0.05, ns = non-significant. 
At least 10 samples per group were pooled from two independent experiments. 
Tconv = conventional T cells, Treg = regulatory T cells. White filled triangles = 




Determining the origin of 2W1S Treg cells 
To better understand the nature of 2W1S+ Treg cells it was important to investigate 
whether they were thymically derived or generated in the periphery from naïve T 
cells. One way to investigate this was to stain for 2W1S+ Treg cells in naïve mice, 
therefore the spleen and a pool of peripheral lymph nodes were harvested from naïve 
FOXP3 GFP mice and enriched for 2W1S-specific T cells. The use of reporter mice 
enhances the number of 2W1S+ Treg cells which can be detected as cells do not 
need to be fixed to identify Treg cells. To further increase the number of 2W1S+ Treg 
cells that could be detected, cells were pooled from two mice after enrichment for 
each sample. Similar to previous studies (Ertelt et al., 2009, Moon et al., 2011), both 
conventional and regulatory 2W1S+ T cells could be identified (Figure 3.7a) (median 
160 and median 23 respectively) (Figure 3.7b). It has been previously shown that 
the majority of 2W1S+ Treg cells identified in naïve mice express Helios (Moon et al., 
2011), a proposed marker of thymically derived Treg cells (Thornton et al., 2010). 
Neuropilin-1, which is another proposed marker of Treg cells (Weiss et al., 2012, 
Yadav et al., 2012), was found to be expressed by the majority of 2W1S+ Treg cells 
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Figure 3.7: 2W1S+ regulatory T cells can be identified in naïve mice. (A) 
Identification of FOXP3- and FOXP3+ 2W1S: I-Ab+ T cells in naïve FOXP3GFP 
mice. Plots are from two mice combined and are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- and FOXP3+ 
2W1S: I-Ab+ T cells. (C) Identification of Nrp-1 on FOXP3- (left) and FOXP3+ 
(right) 2W1S: I-Ab+ T cells. (D) Percentage of Nrp-1+ FOXP3+ and FOXP3- 2W1S: 
I-Ab+ T cells. (B, D) Bars show medians. Mann–Whitney test, *p < 0.05. At least 4 




To further investigate whether 2W1S+ Treg cells expand from thymically derived Treg 
cells or are induced from naive T cells in the periphery, Helios and Nrp-1 were 
stained for on 2W1S+ Treg cells in WT mice seven days after immunisation with 100 
µg 2W1S peptide. The spleen and a pool of peripheral lymph nodes were harvested 
and enriched for 2W1S-specific T cells. The majority of 2W1S+ Treg cells were again 
found to express Neuropilin-1 (median 84.4%) (Figure 3.8a, b); suggesting that they 
are expanded from Treg cells within the naïve 2W1S+ T cell population. Nrp-1 is also 
expressed on conventional T cells after activation (Weiss et al., 2012) and indeed at 
this time point a proportion of 2W1S+ Tconv cells expressed Nrp-1 (median 55.6%). 
In contrast Helios was not expressed by 2W1S+ Tconv cells, but was expressed by 
approximately 2/3 of 2W1S+ Treg cells (median 57.2%) (Figure 3.8c, d). Those 






Figure 3.8: 2W1S+ regulatory T cells expanded by 2W1S peptide express 
markers associated with generation in the thymus. WT mice were immunised 
intravenously with 2W1S peptide. After 7 days, a pool of lymph nodes and spleen 
were analysed. (A) Identification of Nrp-1 on FOXP3- and FOXP3+ CD44hi2W1S: 
I-Ab+ T cells in WT mice. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− 
cells. Filled light grey line: FOXP3- cells, filled dark grey line: FOXP3+ cells. (B) 
Percentage of Nrp-1+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (C) 
Identification of Helios on FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Filled 
light grey line = FOXP3- cells, filled dark grey line = FOXP3+ cells. (D) Percentage 
of Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (E) Identification of 
Nrp-1+Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab T cells. (F) Percentage of 
Nrp-1+Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (B, D, F) Bars 
show medians. Mann–Whitney test, *p < 0.05. At least 4 mice were pooled from 
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The expression of Helios and Nrp-1 on 2W1S+ Treg cells has also been 
characterized with the addition of agonistic anti-DR3. WT mice were immunised with 
100 µg 2W1S peptide and 10 µg agonistic anti-DR3, the spleen and a pool of 
peripheral lymph nodes were harvested and enriched for 2W1S-specific T cells. 
Consistent with previous data, the majority of 2W1S+ Treg cells expressed 
Neuropilin-1 (median 96.1%) (Figure 3.9a, b) and approximately 3/4 expressed 
Helios (median 76.5%) (Figure 3.9c, d). Again the cells which expressed Helios also 
expressed Nrp-1 (Figure 3.9e, f). There was little Helios expression on 2W1S+ Tconv 
cells and Nrp-1 was expressed by approximately 3/4 of these cells (median 74.5%). 
Together, these data suggest that the 2W1S+ Treg cells identified upon immunisation 








Figure 3.9: 2W1S+ regulatory T cells expanded by 2W1S peptide and 
agonistic anti-DR3 express markers associated with generation in the 
thymus. WT mice were immunised intravenously with 2W1S peptide and 
agonistic anti-DR3. After 7 days, a pool of lymph nodes and spleen were 
analysed. (A) Identification of Nrp-1 on FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T 
cells in WT mice. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. 
Filled light grey line = FOXP3- cells, filled dark grey line = FOXP3+ cells. (B) 
Percentage of Nrp-1+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (C) 
Identification of Helios on FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Filled 
light grey line: FOXP3- cells, filled dark grey line: FOXP3+ cells. (D) Percentage of 
Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (E) Identification of Nrp-
1+Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab T cells. (F) Percentage of Nrp-
1+Helios+ FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. (B, D, F) Bars show 
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Development of an in vivo assay to assess 2W1S+ Treg cell function 
Having expanded 2W1S+ Treg cells using two immunisations of 2W1S peptide and 
agonistic anti-DR3, it was then necessary to test the function of these cells. An in 
vivo assay was therefore developed, based on experiments in which the function of 
2W1S+ Treg cells was determined by measuring IFNγ+ production by 2W1S+ T cells 
in response to Lm-2W1S (Rowe et al., 2012). In these experiments 2W1S+ Treg cells 
expanded in response to constitutive expression of 2W1S peptide as a fetal antigen, 
and peaked at 50% of the 2W1S+ T cell population. As the protocol for Treg 
expansion developed in this study results in a percentage of up to 36%, it was 
considered likely that a similar impaired response might be observed. 
2W1S+ Treg cells were therefore expanded using two immunisations of 50 µg 2W1S 
peptide and 10 µg agonistic anti-DR3, seven days apart. After another seven days 
mice were then infected with 107 Lm-2W1S. Any reduction in the number of 2W1S+ 
Tconv cells, compared to mice infected with Lm-2W1S was interpreted as evidence 
of suppression, along with IFNγ+ production. To stimulate IFNγ+ production mice were 
injected with 50 µg 2W1S peptide and 2.5 µg LPS on the day of analysis. The 2W1S-
specific response was then assessed in a pool of lymph nodes and spleen, which 
were harvested four hours later. It was not necessary to enrich these samples as Lm-
2W1S expands a large number of 2W1S+ Tconv cells. 
When performing this assay, it is important to remember that this method of 
expanding 2W1S+ Treg cells also expands 2W1S+ Tconv cells. To take this into 
account a timeline has been plotted of the number of 2W1S+ Tconv cells in mice 




2W1S alone (Figure 3.10a). This has been constructed using data from earlier 
multiple immunisation experiments, as well as this experiment. Although there is only 
a slight difference between the numbers of 2W1S+ Tconv cells after Lm-2W1S is 
administered to pre-treated mice compared to naïve mice (D21), the precursor 
frequency of 2W1S+ Tconv cells is markedly different. There are thought to be 
approximately 200 2W1S+ T cells in a naïve mouse (Moon et al., 2007), which would 
amount to a 211-fold increase in median number from D14 to D21 in the mice which 
had not received pre-treatment (Figure 3.10b). In contrast, in the mice which 
received two immunisations of 2W1S peptide and agonistic anti-DR3, there was a 
4.9-fold increase in median number from D14 to D21. With 2W1S peptide pre-
treatment alone, which expands fewer 2W1S+ Treg cells as well as 2W1S+ Tconv 
cells, there was a 35.8-fold increase in median number from D14 to D21. Therefore, 
although the difference in 2W1S+ Tconv cells is not very large at D21, the limited 
nature of the expansion from D14 to D21 in pre-treated mice may be consistent with 
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Figure 3.10: 2W1S+ regulatory T cell expansion blunts the subsequent 
response to Lm-2W1S. WT mice were infected intravenously with Lm-2W1S. 
After 7 days mice were immunised intravenously with 2W1S peptide and LPS and 
a pool of lymph nodes and spleen were analysed 4 hours later. A group of each 
cohort were immunised intravenously twice with 2W1S peptide +/- agonistic anti-
DR3 prior to infection with Lm-2W1S, 7 days apart. (A) Enumeration of FOXP3-
CD44hi2W1S: I-Ab+ T cells (Tconv cells). Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. Black filled triangles = no pre-treatment, 
grey filled triangles = 2W1S and agonistic anti-DR3, white filled triangles = 2W1S 
peptide. (B) Fold increase in FOXP3-CD44hi2W1S: I-Ab+ T cells (Tconv cells) after 
administration with Lm-2W1S (from D14-D21). Black filled bar = no pre-treatment, 
grey filled bar = 2W1S and agonistic anti-DR3, white filled bar = 2W1S. (A-B) 
Means ± SEM are shown. At least 10 samples per group were pooled from two 





There was a statistically significant difference in 2W1S+ Tconv cell number between 
the mice administered Lm-2W1S only and those given pre-treatment, with 1.4-fold 
less in the pre-treated mice (median 39275 vs median 27244) (Figure 3.11a, b). This 
is consistent with a tolerised state, supporting Treg cell-mediated suppression. IFNγ 
production was identified in both groups but there was not a significant difference 
between the two (Figure 3.11c). In accordance with a role for these cells, the 
number of 2W1S+ Treg cells identified within the pre-treated mice was 6.5-fold higher 
than the mice given Lm-2W1S only (median 3444 vs median 528) (Figure 3.11d). 
Further to this, the percentage of 2W1S+ Treg cells within the pre-treated mice was 
much higher than in the mice given Lm-2W1S only (median 13.3% vs median 1.5%) 
(Figure 3.10e). Therefore, blunting of a subsequent response following Treg cell 
expansion can be observed in this assay, consistent with Treg cell-mediated 
suppression. It is however, important to note that this experimental approach does 
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  Figure 3.11: Expansion of 2W1S+ regulatory T cells using 2W1S peptide and 
agonistic anti-DR3 blunts the subsequent response to Lm-2W1S. WT mice 
were infected intravenously with Lm-2W1S. After 7 days mice were immunised 
intravenously with 2W1S peptide and LPS and a pool of lymph nodes and spleen 
were analysed 4 hours later. A group of each cohort were immunised 
intravenously twice with 2W1S peptide and agonistic anti-DR3 prior to infection 
with Lm-2W1S, 7 days apart. (A) Identification of FOXP3- and FOXP3+ 
CD44hi2W1S: I-Ab+ T cells, as well as IFNγ expression by CD44hi2W1S: I-Ab+ T 
cells. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) 
Enumeration of FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). (C) Enumeration 
of IFNγ+ CD44hi2W1S: I-Ab+ T cells. (D) Enumeration of FOXP3+ CD44hi2W1S: I-
Ab+ T cells (Treg cells). (E) Percentage of FOXP3+ CD44hi2W1S: I-Ab+ T cells 
(Treg cells). (B-E) Black filled triangles = no pre-treatment, grey filled triangles = 
2W1S peptide and agonistic anti-DR3. Mann–Whitney test, **p < 0.01, ***p < 
0.001, ns = non-significant. At least 10 mice were pooled per group from two 




This assay has also been performed using two immunisations of 2W1S peptide to 
expand Treg cells to ensure that the difference observed in 2W1S+ Tconv cell 
number is not solely due to an effect mediated by the agonistic anti-DR3 antibody. 
Therefore, 2W1S+ Treg cells were expanded using two immunisations of 50 µg 
2W1S peptide, seven days apart. After another seven days mice were then infected 
with 107 Lm-2W1S. To stimulate IFNγ+ production mice were injected with 50 µg 
2W1S peptide and 2.5 µg LPS on the day of analysis. The 2W1S-specific response 
was then assessed in a pool of lymph nodes and spleen, which were harvested four 
hours later. Again, there was a statistically significant 1.4-fold reduction in the 
number of 2W1S+ Tconv cells in the pre-treated mice (median 39275 vs median 
28743) (Figure 3.12a, b), consistent with a tolerised state. There was not a 
significant difference in the median number of IFNγ+ 2W1S+ T cells (Figure 3.12c). 
Again the number of 2W1S+ Treg cells identified within the pre-treated mice was 2.7-
fold higher than the mice given Lm-2W1S only (median 1433 vs median 528) (Figure 
3.12d). Further to this, the percentage of 2W1S+ Treg cells within the pre-treated 
mice was higher than in the mice given Lm-2W1S only (median 5.5% vs median 
1.5%) (Figure 3.12e). Therefore, as this impairment in the 2W1S+ T cell response 
was again observed after two immunisations of 2W1S peptide, these data show that 
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  Figure 3.12: Expansion of 2W1S+ regulatory T cells using 2W1S peptide 
blunts the subsequent response to Lm-2W1S. WT mice were infected 
intravenously with Lm-2W1S. After 7 days mice were immunised intravenously 
with 2W1S peptide and LPS and a pool of lymph nodes and spleen were 
analysed 4 hours later. A group of each cohort were immunised intravenously 
twice with 2W1S peptide prior to infection with Lm-2W1S, 7 days apart. (A) 
Identification of FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells, as well as IFNγ 
expression by CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- CD44hi2W1S: 
I-Ab+ T cells (Tconv cells). (C) Enumeration of IFNγ+ CD44hi2W1S: I-Ab+ T cells. 
(D) Enumeration of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). (E) 
Percentage of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). (B-E) Black filled 
triangles = no pre-treatment, grey filled triangles = 2W1S peptide. Bars show 
medians. Mann–Whitney test, *p < 0.05, ***p < 0.001, ns = non-significant. At 
least 10 mice were pooled per group from two independent experiments. Tconv = 




There are reports that although Treg cells are activated in an antigen-specific manner 
they are able to suppress T cells of a different specificity (Schmidt et al., 2012). To 
assess whether 2W1S+ Treg cells can suppress another T cell population, MHC 
tetramers loaded with peptide 190-201 of LLO were used to detect T cells responding 
to Listeriolysin (LLO), which is a major virulence factor expressed by Listeria 
monocytogenes (Hamon et al., 2012). To assess whether the expansion of 2W1S+ 
Treg cells can affect the subsequent expansion of these LLO+ Tconv cells, 2W1S+ 
Treg cells were first expanded using two immunisations of 50 µg 2W1S peptide and 
10 µg agonistic anti-DR3, seven days apart. After another seven days mice were 
then infected with 107 Lm-2W1S, and seven days later the LLO-specific response 
was assessed in a pool of lymph nodes and spleen. There was not, however, a 
statistically significant difference in the number of LLO+ Tconv cells between pre-
treated mice and those given Lm-2W1S only (Figure 3.13a, b). Similarly, there was 
not a statistically significant difference in the number of IFNγ+ LLO+ T cells, although 
the median number was reduced by 2.6-fold in the mice given pre-treatment (Figure 
3.13c). However, the percentage of IFNγ+ LLO+ T cells was reduced by 1.9 fold 
(median 23 vs median 13), an effect which was statistically significant (Figure 3.13d). 
Therefore, there is some evidence of bystander suppression of LLO+ Tconv cells by 
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  Figure 3.13: Expansion of 2W1S+ regulatory T cells using 2W1S peptide and 
agonistic anti-DR3 does not affect the LLO+ specific response to Lm-2W1S. 
WT mice were infected intravenously with Lm-2W1S. After 7 days mice were 
immunised intravenously with 2W1S peptide and LPS and a pool of lymph nodes 
and spleen were analysed 4 hours later. A group of each cohort were immunised 
intravenously twice with 2W1S peptide and agonistic anti-DR3 prior to infection 
with Lm-2W1S, 7 days apart. (A) Identification of CD44hiLLO: I-Ab+ T cells, as well 
as IFNγ expression by CD44hiLLO: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of CD44hiLLO: I-Ab+ T 
cells (Tconv cells). (C) Enumeration of IFNγ+ CD44hiLLO: I-Ab+ T cells. (D) 
Percentage of IFNγ+ CD44hiLLO: I-Ab+ T cells. (B-D) Black filled triangles = no pre-
treatment, grey filled triangles = 2W1S peptide and agonistic anti-DR3. Bars show 
medians. Mann–Whitney test, ***p < 0.001, ns = non-significant. At least 10 mice 





This experiment was also carried out with two immunisations of 2W1S peptide, and 
no agonistic anti-DR3. Therefore, 2W1S+ Treg cells were expanded using two 
immunisations of 50 µg 2W1S peptide, seven days apart. After another seven days 
mice were then infected with 107 Lm-2W1S, and seven days later the LLO-specific 
response was assessed in a pool of lymph nodes and spleen. Again there was not a 
statistically significant difference in the number of LLO+ Tconv cells between pre-
treated mice and those given Lm-2W1S only (Figure 3.14a, b). Similarly, there was 
not a statistically significant difference in the number of IFNγ+ LLO+ T cells, although 
the median number was reduced by 1.8-fold in the mice given pre-treatment (Figure 
3.14c). The percentage of IFNγ+ LLO+ T cells was reduced by 1.7 fold (median 23 vs 
median 13), although this was not statistically significant (Figure 3.14d). Therefore, 
there is little evidence of bystander suppression of LLO+ Tconv cells by 2W1S+ Treg 
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  Figure 3.14 Expansion of 2W1S+ regulatory T cells using 2W1S peptide does 
not affect the LLO+ specific response to Lm-2W1S. WT mice were infected 
intravenously with Lm-2W1S. After 7 days mice were immunised intravenously 
with 2W1S peptide and LPS and a pool of lymph nodes and spleen were 
analysed 4 hours later. A group of each cohort were immunised intravenously 
twice with 2W1S peptide prior to infection with Lm-2W1S, 7 days apart. (A) 
Identification of CD44hiLLO: I-Ab+ T cells, as well as IFNγ expression by 
CD44hiLLO: I-Ab+ T cells. Plots are pre-gated on CD3+CD4+B220−CD11b− CD11c− 
cells. (B) Enumeration of CD44hiLLO: I-Ab+ T cells (Tconv cells). (C) Enumeration 
of IFNγ+ CD44hiLLO: I-Ab+ T cells. (D) Percentage of IFNγ+ CD44hiLLO: I-Ab+ T 
cells. (B-D) Black filled triangles = no pre-treatment, grey filled triangles = 2W1S 
peptide. Bars show medians. Mann–Whitney test, ns = non-significant. At least 10 
mice were pooled per group from two independent experiments. Tconv = 




Determining the effect of Lm-2W1S infection on subsequent 2W1S+ Treg cell 
expansion 
Treatment with 2W1S peptide +/- agonistic anti-DR3, but not Lm-2W1S, has been 
shown to successfully expand Treg cells from the naïve 2W1S+ T cell population. To 
determine whether 2W1S+ Treg cells can be expanded after Lm-2W1S treatment, 107 
Lm-2W1S was administered to WT mice prior to two injections of 50 µg 2W1S 
peptide and 10 µg agonistic anti-DR3, 7 days apart. Within the same experiment, this 
has been compared to the original protocol of 2W1S+ Treg cell expansion prior to Lm-
2W1S infection. Therefore, 2W1S+ Treg cells were first expanded using two 
immunisations of 50 µg 2W1S peptide and 10 µg agonistic anti-DR3, seven days 
apart. After another seven days mice were then infected with 107 Lm-2W1S, and any 
reduction in the number of 2W1S+ Tconv cells, compared to mice which are infected 
with Lm-2W1S without pre-treatment, was interpreted as evidence of suppression. 
Lm-2W1S was again administered at the same time to control mice as to the pre-
treated mice (D14), and also to another group of control mice at the same time as the 
mice receiving Lm-2W1S prior to 2W1S+ Treg cell expansion. On the day of analysis, 
the 2W1S-specific response was assessed in a pool of lymph nodes and spleen.   
When Lm-2W1S was administered prior to the two injections of 2W1S peptide and 
agonistic anti-DR3, there was a very large expansion of 2W1S+ Tconv cells, despite 
the presence of a large number of 2W1S+ Treg cells (Figure 3.15a). This striking 
difference in mice administered 2W1S peptide and agonistic anti-DR3, compared to 
those administered Lm-2W1S only, translated to a 109.8-fold increase in the median 
number of 2W1S+ Tconv cells (Figure 3.15b). This also constituted a 33.8-fold 




prior to Lm-2W1S infection (median 1362494 vs median 40279), despite both sets of 
mice receiving the same treatments in a different order. In contrast to the previous 
experiment, there was not a statistically significant difference in the number of 2W1S+ 
Treg cells in mice given pre-treatment, compared to those given Lm-2W1S only. 
Despite such a striking expansion of 2W1S+ Tconv cells, a large number of 2W1S+ 
Treg cells could be identified in mice given 2W1S peptide and agonistic anti-DR3 
after Lm-2W1S infection (Figure 3.15c). This number was 90-fold higher than mice 
given Lm-2W1S at the same time (median 33148 vs median 368), and 6-fold higher 
when than mice infected with Lm-2W1S after pre-treatment (median 5489). It is 
important to note however that the percentage of 2W1S+ Treg cells in these mice was 
very low (median 2.3%). Therefore, these data demonstrate that if Lm-2W1S is 
administered prior to multiple injections of 2W1S peptide and agonistic anti-DR3, a 























































































  Figure 3.15: 2W1S+ regulatory T cells can be expanded subsequent to Lm-
2W1S administration, but are unable to prevent a large 2W1S+ conventional 
T cell response. WT mice were infected intravenously with Lm-2W1S, either 7 
days before or after two intravenous immunisations of 2W1S peptide and 
agonistic anti-DR3, 7 days apart. Control mice were infected intravenously Lm-
2W1S at either time-point but had no pre or post-treatment. After 7 days mice 
were immunised intravenously with 2W1S peptide and LPS and a pool of lymph 
nodes and spleen were analysed 4 hours later. (A) Identification of FOXP3- and 
FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- CD44hi2W1S: 
I-Ab+ T cells (Tconv cells). (C) Enumeration of FOXP3+ CD44hi2W1S: I-Ab+ T cells 
(Treg cells). (B, C) Black filled triangles = no pre/post-treatment, grey filled 
triangles = 2W1S peptide and agonistic anti-DR3. Bars show medians. Mann–
Whitney test, ***p < 0.001, ns = non-significant. At least 10 mice were pooled per 
group from two independent experiments. Tconv = conventional T cells, Treg = 





This study aimed to establish a method for generating and tracking antigen specific 
Treg cells, and assessing their function in vivo. This method was based on work 
pioneered by Marc Jenkins, in which an endogenous population of naïve T cells are 
expanded by exposure to their cognate peptide, 2W1S, and identified ex vivo using 
MHC class II tetramers (Moon et al., 2007). This approach has previously been 
successfully used to study CD4 memory T cells (Marriott et al., 2015, Marriott et al., 
2014), as well as foetal antigen-specific Treg cells (Rowe et al., 2012).  
In this study, administration of 2W1S peptide was shown to induce greater 
expansion/generation of 2W1S+ Treg cells relative to 2W1S+ Tconv cells than 
infection with Lm-2W1S. This is consistent with previous reports that Treg cell 
expansion/generation is associated with low dose antigen (Friedman and Weiner, 
1994). Notably, this also limits the expansion of Tconv cells due to the low level of 
expression of co-stimulatory molecules, and therefore has a favourable effect on the 
proportion of Treg cells, as observed in this study. In contrast, Listeria 
monocytogenes infection produces a strong type 1 immune response, with a low 
percentage of Treg cells. Therefore, immunisation with 2W1S peptide was used in 
this study to expand Treg cells, rather than Lm-2W1S administration.  
Although Treg cells comprised approximately 13% of the 2W1S+ T cell population 
following 2W1S peptide administration, the number was very low. Therefore, it was 
necessary to investigate strategies to expand Treg cells. Ideally such a strategy 
would increase the percentage of Treg cells as well as the number, to ensure that the 




often start at a 2:1 ratio of conventional to regulatory T cells (Collison and Vignali, 
2011). Administration of an agonistic anti-DR3 antibody has previously been shown 
to selectively expand Treg cells to 30-35% of the T cell population, and as a result to 
prevent the onset of an animal model of asthma (Schreiber et al., 2010), and 
rejection of a cardiac allograph (Wolf et al., 2012). DR3 is a tumor necrosis factor 
receptor, which is well characterized as a costimulatory molecule for T cell activation 
(Croft, 2009). This agonistic anti-DR3 antibody is thought to cause Treg cell 
expansion by increasing their sensitivity to IL-2 (Schreiber et al., 2010). Consistent 
with these findings, when given along with 2W1S peptide, an increase in the overall 
Treg cell population to 30-35% was observed. However, this antibody increased both 
the regulatory and conventional 2W1S+ T cell populations and therefore did not have 
a selective effect on Treg cells within this T cell population. 
Despite the selective effect of agonistic anti-DR3 on the overall Treg cell population, 
regulatory and conventional T cells have been reported to express similar levels of 
DR3 (Taraban et al., 2011a, Meylan et al., 2011). Further to this, constitutive 
expression of its ligand, TL1A, on dendritic cells has been shown to expand both 
regulatory and conventional T cells, with the net effect being more inflammatory than 
regulatory (Taraban et al., 2011b). To investigate this further, DR3 expression was 
studied on these cells. The overall conventional and regulatory T cell populations 
both exhibited DR3 expression, with approximately 50% of conventional T cells and 
70% of regulatory T cells found to be DR3+. Interestingly, it has been proposed that it 
is not relative expression of DR3 that causes the global increase in the Treg cell 
proportion, but relative availability of cognate antigen (Schreiber and Podack, 2013). 




encounters self-antigen, this is the population which expands upon administration of 
the antibody. This theory would fit with the observation within this study that agonistic 
anti-DR3 increased the regulatory and conventional 2W1S+ populations both by the 
same degree when administered with 2W1S peptide as both subsets would have 
encountered cognate antigen. Within the 2W1S+ population, approximately 30% of 
2W1S+ Tconv cells were found to express compared to 60% of 2W1S+ Treg cells 
seven days after immunisation with 2W1S peptide. That DR3 expression can be 
observed on both 2W1S+ conventional and regulatory T cells is consistent with them 
both being expanded by this agonistic anti-DR3 antibody, particularly as DR3 is 
upregulated on T cells upon activation (Croft, 2009). 
Therefore, a strategy to boost the number of 2W1S+ Treg cells was established and 
further experiments were performed to identify a strategy which would also increase 
the proportion of these cells. Repeated exposure to antigen has been shown to 
increase the percentage of Treg cells either due to anergy induction within the 
conventional T cell population (Eroukhmanoff et al., 2009) or as a result of Treg cell 
proliferation (Rosenblum et al., 2011). In this study, the percentage of 2W1S+ Treg 
cells was indeed increased following two injections of 2W1S peptide, reaching 
approximately 20%. This reflected a selective increase in the number of 2W1S+ Treg 
cells, and was also observed when 2W1S peptide and agonistic anti-DR3 was 
administered twice. This observation has important implications in terms of 
autoantigen-specific immunotherapy for autoimmune disease, where the challenge is 
to boost the number of Treg cells specific for an autoantigen, without exacerbating 
the effector response to that autoantigen. These experiments revealed that the 




immunisations of 2W1S peptide and agonistic anti-DR3 and therefore this protocol 
should be used in subsequent experiments. 
To investigate whether Treg cells are thymically (tTreg cells) or peripherally derived 
(pTreg cells), expression of the Ikaros family transcription factor Helios (Thornton et 
al., 2010) and the Semaphorin III receptor Neuropilin-1 (Weiss et al., 2012, Yadav et 
al., 2012) can be used. Further to this, identification of Treg cells which are specific to 
a particular antigen in naïve mice can also provide an indication that the Treg cells 
are thymically derived. It has previously been shown that approximately 7.5% of the 
naïve 2W1S+ T cell population is FOXP3+ and that these Treg cells express Helios 
(Moon et al., 2011). In this study, 2W1S+ Treg cells were also identified in naïve mice 
and the majority were shown to express Neuropilin-1 (Nrp-1). In addition, after 
immunisation with 2W1S peptide +/- agonistic anti-DR3 the majority of 2W1S+ Treg 
cells expressed Nrp-1 (85-95%) and 55-75% expressed Helios. Together this 
suggests that 2W1S+ Treg cells which we are able to identify upon immunisation 
arise due to expansion of thymically derived Treg cells within the naïve 2W1S+ T cell 
pool.  
As previously described, there are concerns about the reliability of in vitro assays, 
such as suppression assays. Therefore in this study, an assay was developed to 
assess the function of antigen-specific Treg cells in vivo, based on work published by 
Rowe et al. (2012). To first expand 2W1S+ Treg cells, the previously established 
protocol was used: two immunisations of 2W1S peptide and agonistic anti-DR3. 
Following Treg cell expansion, mice were infected with Lm-2W1S and any resulting 
impairment in the response, compared to mice given Lm-2W1S only, was considered 




compared between the two groups, there was an impaired response in the mice 
given pre-treatment. Perhaps more strikingly, despite immunisation with 2W1S 
peptide and agonistic anti-DR3 expanding 2W1S+ Tconv cells, and therefore having 
a much larger precursor frequency than naïve mice, both groups of mice infected 
with Lm-2W1S had similar numbers of 2W1S+ Tconv cells. This is consistent with a 
tolerised state, and therefore with the action of 2W1S+ Treg cells. Further to this, the 
response was also blunted when the pre-treatment consisted of two immunisations of 
2W1S peptide alone, which demonstrates that it is not solely mediated by agonistic 
anti-DR3. Therefore, these data indicate that the response to Lm-2W1S is impaired 
following Treg cell expansion, which is consistent with suppression. It is however 
possible that T cell anergy may be instead occurring, a phenomenon which may 
occur upon antigen presentation in the absence of adequate co-stimulation (Harding 
et al., 1992). Further experiments therefore needed to confirm that the impairment in 
the response is a direct result of Treg cell activity, rather than effects on the Tconv 
cell population. Such experiments could be performed using FOXP3DTR mice, in 
which Treg cells can be specifically depleted by addition of diphtheria toxin (Kim et 
al., 2007). It is also important to note that variability has been observed in the 
augmentation of the response in WT mice across all experiments performed. This 
may however, be due to variability in Treg cell percentage, with an impairment 
observed only if the Treg percentage is above a certain threshold. Together these 
data establish a method to study the survival and function of thymically-derived Treg 
cells in an antigen-specific manner.  
Treg cells are also known to have the capacity to suppress T cells of multiple 




Shevach, 1998), although they are activated in an antigen-specific manner and are 
thought to most efficiently suppress T cells of the same specificity (Corthay, 2009). In 
this study, MHC tetramers loaded with peptide 190-201 of LLO were used to detect T 
cells responding to Listeriolysin (LLO), which is expressed by Lm-2W1S (Hamon et 
al., 2012). It was therefore possible to investigate whether 2W1S+ Treg cells augment 
Lm-2W1S mediated expansion of LLO+ Tconv cells. Upon 2W1S peptide and 
agonistic anti-DR3 administration, the number of LLO+ Tconv cells was similar in both 
groups and the number of IFN+LLO+ Tconv cells was modestly reduced, although this 
was not statistically significant. However, the percentage of IFN+LLO+ Tconv cells 
was significantly reduced, which is be consistent with suppression of the response. 
Upon 2W1S peptide administration, the number of LLO+ Tconv cells was similar in 
both groups and there were modest reductions in the number and percentage of 
IFN+LLO+ Tconv cells, although this was not statistically significant. Therefore, some 
evidence of bystander suppression was observed within these experiments, although 
the number of LLO+ Tconv cells was not affected 
One potential therapeutic avenue to reduce tissue damage in autoimmune disease is 
to expand Treg cells either in vivo, or ex vivo prior to transfer (Miyara et al., 2014). 
However, as clinical symptoms occur after the immune response is already 
underway; it is not always possible to expand Treg cells beforehand. Therefore, in 
this study, 2W1S+ Treg cells have been expanded following Lm-2W1S infection, 
again using 2W1S peptide and agonistic anti-DR3. Using this protocol, 2W1S+ Treg 
cell expansion was observed, but these cells comprised only a very small percentage 
of the 2W1S+ T cells, as there was a very large expansion of 2W1S+ Tconv cells. The 




Treg cells suggests that after a strong Th1 response, suppression is more difficult to 
achieve and therefore this approach to the treatment of autoimmune disease may be 
technically challenging. This may reflect differences in the ratio of Treg cells to 
effector cells or enhanced resistance of effector cells to Treg cell-mediated 
suppression. There are indeed reports that high doses of antigen can render effector 
T cells resistant to suppression (Baecher-Allan et al., 2002, Georger et al., 2003), 
with contributions from PAMPS, pro-inflammatory cytokines and co-stimulatory 
molecules (Walker, 2009). However, it is important to note that in these experiments, 
Treg cells were successfully expanded after clearance of Lm-2W1S, and therefore it 
is at unclear whether these mechanisms are involved in the effect observed.  
Therefore, in addition to establishing a method to study Treg cells in an antigen-
specific manner these data explore the concept of ‘bystander suppression’ and 
demonstrate that suppression of a Th1 response is more readily achieved if Treg 
cells are induced before challenge than after. 












4.0 THE ROLE OF TNF RECEPTORS OX40 AND CD30 IN 














TNF receptors such as OX40, which is constitutively expressed on Treg cells (Croft, 
2009), have been proposed as attractive targets for cancer immunotherapy as 
blocking of these receptors may have dual anti-tumor effects, expanding effector T 
cells as well as turning off Treg cell function (Kitamura et al., 2009). OX40 is 
expressed on naïve T cells 12-24 hours after stimulation through the T cell receptor 
and CD28 (Gramaglia et al., 1998, Walker et al., 1999, Gilfillan et al., 1998), where it 
promotes survival (Rogers et al., 2001, Song et al., 2005). Further to this, OX40 has 
been shown to be important for the generation of CD4 T cell memory (Gramaglia et 
al., 2000, Withers et al., 2009). Therefore, in the absence of OX40, CD4 T cell 
expansion is impaired, which may lead to the formation of less memory T cells. 
Interestingly, these effects are enhanced if the TNF receptor CD30 is also absent, 
which suggests that there may be some redundancy in the signalling pathways 
between these two receptors (Gaspal et al., 2005, Gaspal et al., 2008). This 
suggests that considering CD30 as well as OX40 when developing new therapeutics 
may be beneficial, however little is currently known about the importance of CD30. In 
addition, although the hope is that agonistic anti-OX40 would suppress Treg cell 
function; there is controversy in the literature about the role of OX40 on these cells.  
It has been reported that 7-8 week old OX40 KO mice have lower numbers of Treg 
cells (Takeda et al., 2004). Further to this, OX40 expression by Treg cells, as well as 
Tconv cells, has been shown to be associated with survival upon treatment with anti-
lymphocyte serum (Kroemer et al., 2007). These data indicate that OX40 may play a 
role in the survival and/or generation of Treg cells. However, it is now well 




WT (Vu et al., 2007, Tang et al., 2003, Valzasina et al., 2005, Takeda et al., 2004, 
Kroemer et al., 2007).  
In terms of function, Treg cells from OX40 KO mice have been shown to be less 
effective in vitro at suppressing effector T cell proliferation and cytokine production, 
whereas Treg cells from mice overexpressing OX40L have been shown to be more 
effective (Takeda et al., 2004). Further to this, OX40 KO Treg cells are unable to 
prevent T cell-induced colitis (Griseri et al., 2010, Piconese et al., 2010). Together 
this suggests that OX40 is necessary for Treg cell function. In contrast another 
publication has shown that OX40 is dispensable for suppression (Vu et al., 2007). 
Additionally, stimulation of OX40 in vitro using an agonistic OX40 antibody (OX86) or 
mice overexpressing OX40L, has been shown to abrogate the suppressive ability of 
Treg cells (Kitamura et al., 2009, Vu et al., 2007, Xiao et al., 2012, Valzasina et al., 
2005, Piconese et al., 2008, Takeda et al., 2004, Kroemer et al., 2007). This has 
been reported to be coupled with FOXP3 downregulation (Vu et al., 2007, Kitamura 
et al., 2009) and it has been shown that suppression can be restored if Treg cells are 
depleted of OX40 (Vu et al., 2007). Treg mediated suppression has also been shown 
to be impaired upon OX40 stimulation in murine models of skin allograft rejection (Vu 
et al., 2007), graft versus host disease (Valzasina et al., 2005) and colitis (Takeda et 
al., 2004), as well as anti-tumor responses (Houot and Levy, 2009, Kitamura et al., 
2009, Piconese et al., 2008). Notably, OX40 signaling also inhibits conversion of 
naïve T cells into regulatory T cells in vitro and in vivo (Vu et al., 2007, So and Croft, 
2007, Ito et al., 2006, Duan et al., 2008). 
Despite these findings, OX40 stimulation, either due to OX86 or OX40L 




al., 2008, Ruby et al., 2009, Hirschhorn-Cymerman et al., 2009, Xiao et al., 2012, 
Takeda et al., 2004). This can result in ‘exhaustion’ and therefore downregulation of 
FOXP3 and CD25, as well as impaired suppressive ability (Xiao et al., 2012). The 
provision of exogenous IL-2 can however prevent exhaustion, and if IL-2/anti-IL-2 
complexes are given with OX86, long term allograft survival can be observed (Xiao et 
al., 2012). This suggests that the previously described negative effects of OX40 
stimulation on Treg function in vitro and during rejection, colitis and anti-tumor 
responses may be due to the limited availability of IL-2 to Treg cells. 
IL-2 is known to be vital for Treg cell survival (Malek and Castro, 2010) and 
interestingly Treg cells are thought to display altered IL-2 signaling to effector T cells, 
with co-operation with other receptors such as the T cell receptor required for full 
signaling (Bensinger et al., 2004). OX40 signaling on Treg cells has been shown to 
result in Akt activation, which is necessary for full signaling, and is not achieved 
through IL-2 in Treg cells (Xiao et al., 2012). This suggests that signals through 
OX40 and IL-2R may co-operate towards responsiveness to IL-2, and indeed, OX40 
KO Treg cells have been shown to be hypo responsive to IL-2 (Piconese et al., 2010, 
Xiao et al., 2012). This may explain why OX40 KO Treg cells have been shown to be 
less effective in T cell induced colitis (Griseri et al., 2010, Piconese et al., 2010), as 
the absence of OX40 puts them at a disadvantage against effector T cells, with which 
they are competing with for IL-2. 
Therefore the role of these TNF receptors in Treg cell survival and function is unclear 
and it is often difficult to uncouple these two characteristics (Vignali, 2012). An 
antigen-specific T cell approach will aid clarification of specific effects on survival 




important to test function in vivo where possible, due to the previously described 
limitations of in vitro suppression assays. This is technically challenging but recent 
studies have provided clear evidence that such approaches are possible (Rowe et al., 
2012). As previous data is consistent with synergy between OX40 and CD30 (Gaspal 
et al., 2005, Gaspal et al., 2008, Withers et al., 2009, Gaspal et al., 2011), 
experiments have been performed using OX40/CD30 double Knock Out (dKO) mice 






Treg cell expansion and survival in OX40/CD30 dKO mice 
To investigate whether OX40 and CD30 are involved in the expansion and 
persistence of 2W1S+ Treg cells, OX40/CD30 dKO and WT mice were immunised 
twice with 50 µg 2W1S peptide and 10 µg agonistic anti-DR3, seven days apart. This 
protocol for 2W1S+ Treg cell expansion was used as it expands the greatest number, 
aiding detection at longer time points, anticipating low numbers of 2W1S+ Treg cells. 
On either day 7, 21 or 51 after the second injection of 2W1S peptide and agonistic 
anti-DR3, the spleen and a pool of peripheral lymph nodes were harvested from 
these mice and enrichment of 2W1S+ T cells was performed.  
Treg cell numbers were analysed along with the number of conventional T cells as a 
comparison, due to the well characterized role of TNF receptors in promoting T cell 
survival during a primary response (Croft, 2009). At all timepoints studied, both 
regulatory and conventional 2W1S+ T cells could be detected (Figure 4.1a). At day 7 
after the final immunisation, there were significantly fewer 2W1S+ Treg cells in the 
OX40/CD30 dKO mice than in WT mice, which amounted to a 2.7-fold reduction in 
number (Figure 4.1b) (median 1188 vs median 444). Similarly, a 4.4-fold reduction in 
the number of 2W1S+ Tconv cells was observed between WT and OX40/CD30 dKO 
mice (median 7242 vs median 1649) (Figure 4.1c), indicating that the optimal 
expansion of both regulatory and conventional T cells is dependent on OX40 and 
CD30. These data do suggest, however, that Treg cells are marginally less 




After 51 days, the significant reduction in the number of 2W1S+ Tconv cells (2.5 fold; 
median 1399 vs median 557) but not 2W1S+ regulatory T cells remained. Therefore, 
long term survival of these antigen specific Treg cells appears to be comparable in 
the absence of OX40 and CD30 despite reduced numbers at day 7. A time point 
between day 7 and 51 was also studied to determine whether signaling through 
OX40 and CD30 may have a role within this time period. At day 21 after the final 
immunisation, there was again no significant difference in the numbers of 2W1S+ 
Treg cells in OX40/CD30 dKO mice compared to WT. The number of 2W1S+ Tconv 
cells was also unchanged between dKO and WT mice. Overall these data indicate 
that following expansion of 2W1S+ T cells, the survival of conventional but not 
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  Figure 4.1: Expansion of regulatory and conventional antigen-specific T 
cells is impaired in mice which lack OX40 and CD30. WT and OX40/CD30 
dKO mice were immunised twice with 2W1S peptide and agonistic anti-DR3 
antibody intravenously, 7 days apart. 7, 21 or 52 days after the second 
immunisation, a pool of lymph nodes and spleen were analysed. (A) Identification 
of FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- CD44hi2W1S: 
I-Ab+ T cells (Tconv cells). (C) Enumeration of FOXP3+ CD44hi2W1S: I-Ab+ T cells 
(Treg cells). (B, C) Bars show medians. Mann–Whitney test, *p < 0.05, **p < 0.01, 
ns = non-significant. At least 8 mice were pooled per group from two independent 




Further investigation of the role of OX40 and CD30 in Treg cell function 
Given the modest effects of the absence of OX40 and CD30 on Treg cell survival, 
possible defects in Treg function were investigated. Treg cells from the spleen and 
lymph nodes of OX40/CD30 dKO mice were therefore analysed for expression of 
FOXP3, which is critical for Treg cell function (Fontenot et al., 2003, Hori et al., 
2003). In addition, the expression of CTLA-4, CD25, CD39 and CD73, which are key 
molecules involved in suppression (Schmidt et al., 2012), was also analysed. Total 
Treg cells were first studied, followed by the 2W1S+ Treg cell population. 
Treg cell enumeration revealed that the median number of Treg cells in mice lacking 
OX40 and CD30 was 2.1 fold lower than WT mice (Figure 4.2a). In this total Treg cell 
population, there was not a significant difference in the expression of FOXP3, 
suggesting that Treg cell function is intact (Figure 4.2b, c). In addition, there were 
not any significant differences in expression of CTLA-4, CD25 or CD39 between 
OX40/CD30 dKO and WT mice (Figure 4.2d, e). There was however a modest but 
significant reduction in the expression of CD73, which amounted to a 1.4-fold 
reduction in median florescence intensity (2186 vs 1608). Again conventional T cells 
have been used for comparison within this experiment. As expected within the global 
Tconv cell population, there was little expression of CTLA-4, CD25 and CD39, which 
are upregulated upon activation. CD73 was, however, expressed by a proportion of 






































































   Figure 4.2: Expression of key molecules involved in regulatory cell function 
is not dependent on OX40 and CD30. (A) Enumeration of FOXP3+ CD4+ T cells 
(Treg cells). (B) Identification of FOXP3 expression within Treg cells from WT and 
OX40/CD30 dKO mice. Expression within WT conventional T cells is also shown 
for comparison. (C) Median Florescence Intensity (MFI) of FOXP3 within Treg 
cells from WT and OX40/CD30 dKO mice. (D) Identification of CTLA-4, CD25, 
CD39 or CD73 expression on Treg cells from WT and OX40/CD30 dKO mice. 
Expression on WT conventional T cells is also shown for comparison. (E) Median 
Florescence Intensity (MFI) of CTLA-4, CD25, CD39 and CD73 on Treg cells from 
WT and OX40/CD30 dKO mice. (B, D) Plots are gated on FOXP3+ 
CD3+CD4+B220−CD11b−CD11c− cells. Filled grey line = WT Tconv cells, Solid 
black line = WT Treg cells, Dotted black line = dKO Treg cells. (C, E) Bars show 
medians. Mann–Whitney test, *p < 0.05, ns = non-significant. At least 4 mice were 
pooled per group from two independent experiments. Tconv = conventional T 




To characterize expression of these markers on 2W1S+ Treg cells, WT and 
OX40/CD30 dKO mice were immunized twice with 50 µg 2W1S peptide and 10 µg 
agonistic anti-DR3 7 days apart.  The spleen and a pool of peripheral lymph nodes 
were harvested seven days later from these mice and enrichment of 2W1S-specific T 
cells was performed. In accordance with the data from figure 4.2, the median number 
of 2W1S+ Treg cells was 2.3 fold lower in mice lacking OX40 and CD30 compared to 
WT, although this did not reach statistical significance (Figure 4.3a). There were not 
any significant differences in the expression of FOXP3 (Figure 4.3b, c), CTLA-4, 
CD25 or CD73 (Figure 4.3d, e). However, there was a modest but significant 
reduction in the expression of CD39, which amounted to a 1.6-fold reduction in 
median florescence intensity (893 vs 568). These data therefore indicate that Treg 
cells from OX40/CD30 dKO mice are not substantially impaired in their expression of 
key molecules involved in Treg cell function. Expression of these markers on 2W1S+ 
Tconv cells has again been displayed on the histograms for comparison. In contrast 
to the total Tconv cells (Figure 4.2d, e) CD25 was expressed by a proportion of these 
cells as it is upregulated on T cells upon activation (Malek and Castro, 2010). In 
addition, CD73 was found to be expressed by all 2W1S+ Tconv cells. This is perhaps 
surprising as CD73 has previously been described as a marker of Treg cells (Deaglio 
et al., 2007). However, it has also been reported to be expressed on CD25- primed 











































































   Figure 4.3: Expression of key molecules involved in (2W1S+) regulatory cell 
function is not dependent on OX40 and CD30. WT and OX40/CD30 dKO mice 
were immunised twice with 2W1S peptide and agonistic anti-DR3 antibody 
intravenously. (A) Enumeration of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). 
(B) Identification of FOXP3 expression within 2W1S+ Treg cells from WT and 
OX40/CD30 dKO mice. Expression within WT 2W1S+ conventional T cells is also 
shown for comparison. (C) Median Florescence Intensity (MFI) of FOXP3 within 
2W1S+ Treg cells from WT and OX40/CD30 dKO mice. (D) Identification of CTLA-
4, CD25, CD39 or CD73 expression on 2W1S+ Treg cells from WT and 
OX40/CD30 dKO mice Expression on WT 2W1S+ conventional T cells is also 
shown for comparison. (E) Median Florescence Intensity (MFI) of CTLA-4, CD25, 
CD39 and CD73 on 2W1S+ Treg cells from WT and OX40/CD30 dKO mice. (B, D) 
Plots are pre-gated on Plots are pre-gated on CD3+CD4+B220−CD11b− CD11c− 
cells and then FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). Filled grey line = 
WT Tconv cells, Solid black line = WT Treg cells, Dotted black line = dKO Treg 
cells. (C, E) Bars show medians. Mann–Whitney test, *p < 0.05, ns = non-
significant. At least 4 mice were pooled per group from three independent 




This study has shown that 2W1S+ Treg cells do not exhibit gross defects in 
persistence or expression of some key suppressive molecules in OX40/CD30 dKO 
mice. To further assess function, experiments were performed to test whether 
expanded 2W1S+ Treg cells are able to suppress a subsequent 2W1S+ T cell 
response. This in vivo assay was based on experiments in which the function of 
2W1S+ Treg cells was determined by measuring IFNγ+ production by 2W1S+ T cells 
in response to Lm-2W1S (Rowe et al., 2012). In these experiments 2W1S+ Treg cells 
expanded in response to constitutive expression of 2W1S peptide as a fetal antigen, 
and peaked at 50% of the 2W1S+ T cell population. As the protocol for Treg 
expansion developed in this study results in a percentage of up to 36%, it was likely 
that a similar impaired response would be observed. 2W1S+ Treg cells were 
therefore expanded in WT and OX40/CD30 dKO mice using two immunisations of 50 
µg 2W1S peptide and 10 µg agonistic anti-DR3 seven days apart. To determine 
whether the presence of 2W1S+ Treg cells augments the subsequent response to 
Lm-2W1S, seven days after the final injection of 2W1S peptide and agonistic anti-
DR3, mice were infected with 107 Lm-2W1S. On the day of analysis, seven days 
later, mice were injected with 50 µg 2W1S peptide and 2.5 µg LPS to stimulate 
cytokine production. The 2W1S-specific response was then assessed in a pool of 
lymph nodes and spleen, which were harvested four hours later.  
In the WT controls, fewer 2W1S+ Tconv cells were detected in mice which had been 
previously immunised with 2W1S peptide and agonistic anti-DR3 compared to than 
those infected with Lm-2W1S without pre-treatment (Figure 4.4a), and this 2.2-fold 
reduction in numbers was statistically significant (median 32942 vs median 15014) 




number in the OX40/CD30 dKO mice between those pre-treated and those which 
were not. This augmentation of the response in WT but not OX40/CD30 dKO mice is 
consistent with impairment in the function of OX40/CD30 dKO Treg cells. In WT 
mice, there was a trend towards reduced IFNγ production by 2W1S+ Tconv cells 
between those pre-treated and those which were not, although this was not 
statistically significant (Figure 4.4c). Strikingly, these data revealed that IFNγ 
production was very low in OX40/CD30 dKO mice, which could be significantly 
increased upon pre-treatment.  
It was important to confirm that Treg cells had been successfully expanded in WT 
and OX40/CD30 dKO mice given the pre-treatment (two immunisations of 2W1S 
peptide and agonistic anti-DR3). A population of 2W1S+ Treg cells could indeed be 
identified in WT and dKO mice (Figure 4.4d), with a median percentage of 16 in WT 
mice and 8.1 in OX40/CD30 dKO mice (Figure 4.4e). Therefore, these data show 
augmentations of the 2W1S+ Tconv cell response in WT mice, which is not detected 
in OX40/CD30 dKO mice. This is consistent with the function of OX40/CD30 dKO 
Treg cells being impaired. It is however, important to note that this experimental 
approach does not directly demonstrate Treg cell involvement. Furthermore, 
variability has been observed in the augmentation of the response in WT mice across 
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Figure 4.4: The absence of OX40 and CD30 impairs regulatory T cell 
function. WT and OX40/CD30 dKO mice were infected with Lm-2W1S 
intravenously. After 7 days a four hour in vivo stimulation with 2W1S peptide was 
performed and a pool of lymph nodes and spleen were analysed. A group of each 
cohort were immunised twice with 2W1S peptide and agonistic anti-DR3 antibody 
intravenously prior to infection with Lm-2W1S, 7 days apart. (A) Identification of 
CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on CD3+CD4+B220−CD11b− 
CD11c− cells. (B) Enumeration of FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). 
(C) Enumeration of IFNγ+ CD44hi2W1S: I-Ab+ T cells. (D) Identification of FOXP3+ 
CD44hi2W1S: I-Ab+ T cells (Treg cells) in the group of WT and OX40/CD30 dKO 
mice immunised twice with 2W1S peptide and agonistic anti-DR3. Plots are pre-
gated on CD3+CD4+B220−CD11b−CD11c− cells. (E) Percentage of FOXP3+ 
CD44hi2W1S: I-Ab+ T cells (Treg cells). (B, C, E) Bars show medians. Mann–
Whitney test, ***p < 0.001, **p < 0.01, *p < 0.05, ns = non-significant. Between 5-
10 mice were pooled per group from two independent experiments. Tconv = 




Investigating the role of OX40 and CD30 in effector cytokine production 
A striking observation from this in vivo assay is the impaired production of IFNγ by 
2W1S+ Tconv cells from OX40/CD30 dKO mice. As earlier data showed that Tconv 
cell expansion and survival was impaired in OX40/CD30 dKO mice but only by 4.4 
and 2.5 fold respectively, it may be that the key role of OX40 and CD30 on Tconv 
cells is in their function. To study this in more detail, WT and OX40/CD30 dKO mice 
were infected with 107 Lm-2W1S and were injected with 50 µg 2W1S peptide and 2.5 
µg LPS seven days later to stimulate cytokine production. The 2W1S-specific 
response was then assessed in a pool of lymph nodes and spleen, which were 
harvested four hours later. Significantly fewer 2W1S+ Tconv cells were identified in 
the OX40/CD30 dKO than WT mice (Figure 4.5a). This 1.4-fold difference in median 
number (Figure 4.5b) and 1.7-fold difference in median percentage (Figure 4.5c) 
demonstrates that although reduced, 2W1S+ Tconv cell expansion does occur in 
these mice in response to Lm-2W1S. Their ability to produce the effector cytokines 
upon in vivo stimulation with 2W1S peptide and LPS however was grossly impaired, 
as is demonstrated by the 5.9-fold reduction in the number of IFNγ+ 2W1S+ Tconv 
cells (median 11382 vs median 1936) (Figure 4.5d) and 4.3-fold reduction in the 
percentage of 2W1S+ Tconv cells which express this effector cytokine (median 
34.3% vs median 8.1%) (Figure 4.5e). This suggests that signals through OX40 and 
























































































   Figure 4.5: OX40 and CD30 are required for effector cytokine production by 
2W1S+ T cells. WT and OX40/CD30 dKO mice were infected intravenously with 
Lm-2W1S. After 7 days a four hour in vivo stimulation with 2W1S peptide was 
performed and a pool of lymph nodes and spleen were analysed. (A) Identification 
of CD44hi2W1S: I-Ab+ T cells, followed by IFNγ+ CD44hi2W1S: I-Ab+ T cells. Plots 
are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of 
FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). (C) Percentage of FOXP3- 
CD44hi2W1S: I-Ab+ T cells (Tconv cells). (D) Enumeration of IFNγ+ FOXP3- 
CD44hi2W1S: I-Ab+ T cells. (E) Percentage of IFNγ+ FOXP3- CD44hi2W1S: I-Ab+ T 
cells. (B-E) Bars show medians. Mann–Whitney test, ***p < 0.001, ns = non-
significant. At least 9 mice were pooled per group from three independent 




To provide further evidence that Tconv cells from OX40/CD30 dKO mice were 
fundamentally impaired in effector cytokine production; another endogenous T cell 
population was studied after infection with Lm-2W1S. MHC class II tetramers loaded 
with peptide 190-201 of LLO were used to detect T cells responding to Listeriolysin 
(LLO), which is a major virulence factor expressed by Listeria monocytogenes 
(Hamon et al., 2012). Therefore, WT and OX40/CD30 dKO mice were infected with 
107 Lm-2W1S and the LLO-specific response was assessed in a pool of lymph nodes 
and spleen, which were harvested seven days later. Again, significantly fewer LLO+ 
Tconv cells were identified in the OX40/CD30 dKO than WT mice (Figure 4.6a). This 
2.4-fold difference in median number (Figure 4.6b) and 3-fold difference in median 
percentage (Figure 4.6c) demonstrates that although reduced, LLO+ Tconv cell 
expansion does occur in these mice in response to Lm-2W1S. However, the striking 
difference was again the 10.4-fold reduction in the number of IFNγ+ LLO+ Tconv cells 
(median 8343 vs median 804) (Figure 4.6d) and 4.4-fold reduction in the percentage 
of LLO+ Tconv cells which express this effector cytokine (median 16.3% vs median 
3.8%) (Figure 4.6e). Combined, these data demonstrate that in the absence of OX40 




















































































   Figure 4.6: OX40 and CD30 are required for effector cytokine production by 
LLO+ T cells. WT and OX40/CD30 dKO mice were infected intravenously with 
Lm-2W1S. After 7 days a four hour in vivo stimulation with 2W1S peptide was 
performed and a pool of lymph nodes and spleen were analysed. (A) Identification 
of CD44hiLLO: I-Ab+ T cells, followed by IFNγ+ CD44hiLLO: I-Ab+ T cells. Plots are 
pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3- 
CD44hiLLO: I-Ab+ T cells (Tconv cells). (C) Percentage of FOXP3- CD44hiLLO: I-
Ab+ T cells (Tconv cells). (D) Enumeration of IFNγ+ FOXP3- CD44hiLLO: I-Ab+ T 
cells. (E) Percentage of IFNγ+ FOXP3- CD44hiLLO: I-Ab+ T cells. (B-E) Bars show 
medians. Mann–Whitney test, ***p < 0.001, ns = non-significant. At least 9 mice 





The roles of OX40 and CD30 have been investigated in this study as there are 
numerous reports that these two receptors display synergy (Gaspal et al., 2005, 
Gaspal et al., 2008, Withers et al., 2009, Gaspal et al., 2011). To investigate whether 
OX40 deficiency alone results in grossly impaired effector cytokine production, WT 
and OX40 KO mice were infected with 107 Lm-2W1S and seven days later mice were 
injected with 50 µg 2W1S peptide and 2.5 µg LPS to stimulate cytokine production. 
The 2W1S-specific response was then assessed in a pool of lymph nodes and 
spleen, which were harvested four hours later. Significantly fewer 2W1S+ Tconv cells 
were identified in the OX40 KO than WT mice (Figure 4.7a), which amounted to a 
2.2-fold reduction in median number (Figure 4.7b). There was not a significant 
difference in the percentage of 2W1S+ Tconv cells between OX40 KO and WT mice, 
however (Figure 4.7c). Their ability to produce the effector cytokines upon in vivo 
stimulation with 2W1S peptide and LPS however was again abrogated, with a 10.5-
fold reduction in the number of IFNγ+ 2W1S+ Tconv cells (median 10538 vs median 
1004) (Figure 4.7d) and 4.5-fold reduction in the percentage of 2W1S+ Tconv cells 
which express this effector cytokine (median 23.2% vs median 5.2%) (Figure 4.7e). 
Thus the impaired effector cytokine production observed in OX40/CD30 dKO mice 
was attributable to OX40 expression, which is a key determinant of CD4 T cell 



























































































   Figure 4.7: OX40 expression is key to the ability of T cells to produce 
effector cytokines. WT and OX40 KO mice were infected intravenously with Lm-
2W1S. After 7 days a four hour in vivo stimulation with 2W1S peptide was 
performed and a pool of lymph nodes and spleen were analysed. (A) Identification 
of CD44hi2W1S: I-Ab+ T cells, followed by IFNγ+ CD44hi2W1S: I-Ab+ T cells. Plots 
are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of 
FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). (C) Percentage of FOXP3- 
CD44hi2W1S: I-Ab+ T cells (Tconv cells). (D) Identification of FOXP3+ 
CD44hi2W1S: I-Ab+ T cells (Treg cells). (E) Percentage of FOXP3+ CD44hi2W1S: 
I-Ab+ T cells (Treg cells. (B, C, E) Bars show medians. Mann–Whitney test, ***p < 
0.001, ns = non-significant. At least 9 mice were pooled per group from three 




Repeated expansion of 2W1S+ T conventional cells in OX40/CD30 dKO mice 
This study has shown that 2W1S+ T cells display grossly impaired effector cytokine 
production, building on previously published data which indicates that OX40 and 
CD30 are required for functional autoreactive CD4 T cell responses (Gaspal et al., 
2011). In this study it was shown that Treg cells deficient in OX40 and CD30 fail to 
succumb to autoimmunity which results from the absence of Treg cells. To further 
investigate the importance of these TNF receptors in Tconv cell function, chronic 
antigen exposure, as occurs in autoimmunity, was modelled through repeated 
expansion of 2W1S+ Tconv cells. WT and OX40/CD30 dKO mice were therefore 
infected with 107 Lm-2W1S and two injections of 50 µg 2W1S and 10 µg agonistic 
anti-DR3 were then administered seven days apart, starting seven days after the Lm-
2W1S. The 2W1S-specific response was assessed in a pool of lymph nodes and 
spleen, which were harvested seven days later. These two groups of mice were also 
compared to a group of WT and a group of OX40/CD30 dKO mice which were 
infected with 107 Lm-2W1S and analysed seven days later to allow acute antigen 
exposure to be compared to chronic antigen exposure. 
In the WT mice, there was a very large expansion of 2W1S Tconv cells after the 
three injections (Figure 4.8a). The median number of 2W1S+ Tconv cells was 16.5 
fold higher than the WT mice that had been infected with Lm-2W1S seven days 
previously (Figure 4.8b). Additionally, the median percentage of CD4 T cells which 
were 2W1S-specific was 19.8 fold higher in the WT mice which encountered antigen 
repeatedly. In contrast in the OX40/CD30 dKO mice administered the three 
injections; there was only a 2.4-fold increase in the median number of 2W1S+ Tconv 




median percentage of CD4 T cells which were 2W1S-specific was increased by only 
2.9 fold (Figure 4.8c). Therefore, after repeated exposure to antigen, the number of 
2W1S Tconv cells was 12.2 fold higher in the WT mice than OX40/CD30 dKO mice 
(median 820714 vs median 67160), and the percentage was 12.6 fold higher (median 
5.9% vs median 0.5%) (Figure 4.8b, c). These data indicate that in the absence of 
OX40 and CD30, there is a striking impairment in the ability of the antigen-specific T 
cell pool to expand in response to repeated exposure to antigen.  
In this protocol, two immunisations of 2W1S peptide and agonistic anti-DR3 have 
been administered after Lm-2W1S infection. Accordingly, 2W1S+ Treg cells have also 
been expanded within this experiment, although at a low percentage of the 2W1S-
specific T cell population (Figure 4.8d). The number of 2W1S+ Treg cells followed 
the same trend as the 2W1S+ Tconv cell population, with greater expansion observed 
in the WT mice than the OX40/CD30 dKO mice. A 6-fold increase in median 2W1S+ 
Treg cell number was observed in the WT mice, and a 2.5-fold increase in 
OX40/CD30 dKO mice between those administered the three injections and those 
infected with Lm-2W1S seven days previously (Figure 4.8e). Therefore, these data 
demonstrate that OX40 and CD30 are required for T cells to be able to expand in 
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   Figure 4.8: OX40 and CD30 are required for the repeated expansion of T 
cells. WT and OX40/CD30 dKO mice were infected intravenously with Lm-2W1S, 
and either analysed 7 days later, or subsequently given two immunisations of 
2W1S peptide and agonistic anti-DR3 intravenously, 7 days apart. 7 days after the 
final injection, a 4 hour in vivo stimulation with 2W1S peptide was performed on 
all mice and a pool of lymph nodes and spleen were analysed. (A) Identification of 
CD44hi2W1S: I-Ab+ T cells in the group of WT and OX40/CD30 dKO mice 
immunised twice with 2W1S peptide and agonistic anti-DR3 after Lm-2W1S 
administration. Plots are pre-gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) 
Enumeration of FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). (C) Percentage 
of FOXP3- CD44hi2W1S: I-Ab+ T cells (Tconv cells). (D) Identification of FOXP3+ 
CD44hi2W1S: I-Ab+ T cells (Treg cells) in the group of WT and OX40/CD30 dKO 
mice immunised twice with 2W1S peptide and agonistic anti-DR3 after Lm-2W1S 
administration. Plots are pre-gated on CD44hi2W1S: I-Ab+ 
CD3+CD4+B220−CD11b−CD11c− cells. (E) Enumeration of FOXP3+ CD44hi2W1S: 
I-Ab+ T cells (Treg cells). (B, C, E) Bars show medians. Mann–Whitney test, ***p < 
0.001, *p < 0.05, ns = non-significant. Between 6-8 samples per group were 
pooled from two independent experiments. Tconv = conventional T cells, Treg = 





The role of OX40 signaling in Treg cell biology is controversial within the literature, 
with reports that OX40 negatively regulates Treg cell function, and conversely that 
OX40 and IL-2 signal co-operatively to support Treg cells (Xiao et al., 2012). OX40 is 
known to have an important role in CD4 T cell expansion (Rogers et al., 2001, Pippig 
et al., 1999, Chen et al., 1999, Kopf et al., 1999) and therefore the potential that 
OX40 signaling may turn off Treg cell function has led to proposals that agonistic 
OX40 antibodies would have dual anti-tumor effects, by expanding effector T cells 
and turning off Treg cell function (Kitamura et al., 2009). However, with controversy 
surrounding the role of OX40, it is important to fully understand the role of this TNF 
receptor in Treg biology. An antigen-specific system has been used within this study, 
to allow effects on survival and function to be dissected. As OX40 and CD30 have 
been reported to exhibit synergy (Gaspal et al., 2005, Gaspal et al., 2008, Withers et 
al., 2009, Gaspal et al., 2011) the role of both of these TNF receptors has been 
addressed within this study.  
OX40 KO mice have been reported to have similar numbers of Treg cells as WT mice 
(Vu et al., 2007, Tang et al., 2003, Valzasina et al., 2005, Takeda et al., 2004, 
Kroemer et al., 2007), although one study shows that the number is less in 7-8 week 
old OX40 KO mice (Takeda et al., 2004). Treg cell generation in the thymus is 
therefore thought to be independent of OX40. In this study, however, total and 
2W1S+ Treg cell numbers in OX40/CD30 dKO mice were found to be reduced by 
approximately 2 fold. It has also been reported that OX40 promotes Treg cell survival 
(Kroemer et al., 2007). Within this study, persistence of antigen-specific Treg cells 




reduction in the median number of conventional but not regulatory 2W1S+ T cells, 
which indicates that survival of Treg cells is not highly dependent on OX40 and 
CD30. It is important to note that it is possible that there is also synergy between 
these TNF receptors and other members of this superfamily, and therefore other TNF 
receptors may be compensating for the loss of OX40 and CD30. 
OX40 stimulation has been shown to result in Treg cell proliferation in vivo, similar to 
the effect on Tconv cells (Hippen et al., 2008, Ruby et al., 2009, Hirschhorn-
Cymerman et al., 2009, Xiao et al., 2012, Takeda et al., 2004). In addition, there is 
evidence that the absence of OX40 renders Treg cells less responsive to IL-2 
(Piconese et al., 2010, Xiao et al., 2012), which is required for Treg cell activation 
and survival (Malek and Castro, 2010). The initial expansion of 2W1S+ Treg cells in 
response to 2W1S peptide and agonistic anti-DR3 was shown in this study to be 
significantly reduced in OX40/CD30 dKO mice, although less so than the number of 
2W1S+ Tconv cells. As evidence within this study suggests that 2W1S+ Treg cells are 
thymically derived, the difference observed in 2W1S+ Treg cell numbers cannot be 
accounted for by this reduction in 2W1S+ Tconv cells. This therefore suggests that 
there is a role for OX40 and CD30 in expansion of Treg cells; however, it is important 
to note that Treg cells were less affected than Tconv cells. 
The role of OX40 in Treg cell function is also controversial. There are conflicting 
reports from in vitro suppression assays using OX40 KO Treg cells, with one study 
showing suppression is impaired in the absence of OX40 (Takeda et al., 2004), and 
another showing that OX40 is dispensable (Vu et al., 2007). Consistent with the 
latter, OX40 KO Treg cells are unable to prevent the onset of T cell-induced colitis 




Treg function, although paradoxically, stimulation of OX40 in vitro using an agonistic 
OX40 antibody (OX86) or mice overexpressing OX40L, has been shown to abrogate 
the suppressive ability of Treg cells (Kitamura et al., 2009, Vu et al., 2007, Xiao et al., 
2012, Valzasina et al., 2005, Piconese et al., 2008, Takeda et al., 2004, Kroemer et 
al., 2007). Additionally, Treg mediated suppression is impaired upon OX40 
stimulation in murine models of skin allograft rejection (Vu et al., 2007), graft versus 
host disease (Valzasina et al., 2005), colitis (Takeda et al., 2004) as well as anti-
tumor responses (Houot and Levy, 2009, Kitamura et al., 2009, Piconese et al., 
2008). Interestingly, it appears that much of the dichotomy within the literature may 
be due to the availability of IL-2. The majority of studies which suggest that OX40 is a 
negative regulator of Treg function include experiments in which OX40 is stimulated 
by OX86. This leads to Treg proliferation, and hence an increased requirement for IL-
2, which can lead to exhaustion if IL-2 levels are limiting, and a resulting functional 
impairment. IL-2 may become limiting in vitro or if the antibody is given in vivo during 
an immune response, when Treg cells must compete with activated T cells, which 
also express OX40, for IL-2. 
This study revealed no differences in FOXP3 expression by total and 2W1S+ Treg 
cells from OX40/CD30 dKO mice, which is a crucial transcription factor for Treg cell 
function (Fontenot et al., 2003, Hori et al., 2003). Further to this, the expression of 
key molecules involved in suppression was largely similar between total and 2W1S+ 
Treg cells from OX40/CD30 dKO and WT mice. This included CTLA-4, which 
reduces antigen presentation through interactions with the co-stimulatory molecules 
CD80 and CD86 on antigen presenting cells (Qureshi et al., 2011), and CD25, which 




2005). The ectoenzymes CD39 and CD73 are also thought to disrupt the metabolism 
of effector T cells, in this case though production of adenosine, which inhibits their 
proliferation (Kobie et al., 2006, Deaglio et al., 2007, Borsellino et al., 2007). The 
expression of CD73 was found to be significantly lower on total Treg cells but not 
2W1S+ Treg cells from OX40/CD30 dKO mice. Conversely, expression of CD39 was 
found to be significantly lower on 2W1S+ Treg cells but not total Treg cells from 
OX40/CD30 dKO mice. The absence of OX40 and CD30 therefore may affect the 
expression of ectoenzymes which Treg cells utilize to disrupt effector T cells, 
however no evidence was found of other mechanisms being affected. This supports 
the findings of Vu et al. (2007), who postulate that OX40 is dispensable for 
suppression. However, it is important to note that Treg cells employ a range of 
mechanisms (Schmidt et al., 2012), within which there may be redundancy. In 
addition, Treg cells also suppress a variety of cell types (Schmidt et al., 2012) and it 
has been reported that OX40 expression on Treg cells mediates suppression of mast 
cell degranulation (Gri et al., 2008).  
There has been concern within the field that too strong conclusions have been drawn 
about Treg cell function from in vitro assays, which do not provide sufficient evidence  
(Vignali, 2012). In this study, an in vivo assay was therefore used to investigate Treg 
cell function. This in vivo assay demonstrated that after expansion of 2W1S+ Treg 
cells, the subsequent response to Lm-2W1S is augmented in WT but not 
OX40/CD30 dKO mice. This suggests that the function of OX40/CD30 dKO Treg 
cells is impaired. Further experiments in mice which can be conditionally depleted of 
Treg cells are needed to confirm that the impairment in the response to Lm-2W1S 




most effective model for studying this would be to use ‘FOXP3DTR’ mice, which are 
engineered so that the Diphtheria Toxin Receptor (DTR) is expressed by Treg cells, 
and therefore these cells can be specifically ablated by administration of Diphtheria 
Toxin (Kim et al., 2007). 
As previously discussed, OX40 and CD30 have been shown to promote survival 
during T cell activation and the generation of CD4 T cell memory. Further to this, the 
absence of OX40 and CD30 has been shown to protect mice from lethal 
autoimmunity which results from the absence of Treg cells (Gaspal et al., 2011), 
implying a role in CD4 T cell function. T cells from these OX40/CD30 dKO mice were 
shown to produce significantly less IFNγ upon stimulation. This effector cytokine is 
the key mediator produced by T helper 1 (Th1) cells, particularly through its effects 
on macrophages where signaling through the IFNγ receptor leads to increased 
antigen presentation and bactericidal  activity (Schroder et al., 2004). Interestingly, a 
human patient deficient in OX40 has been shown to display impaired IFNγ production 
upon exposure to previously encountered antigens (Byun et al., 2013). This therefore 
suggests that the generation of a functional CD4 T cell response is dependent on 
OX40 and CD30.  
Data within this study show that seven days after infection with Listeria 
monocytogenes-expressing 2W1S, which induces a strong Th1 response (Spellberg 
and Edwards, 2001), the ability of 2W1S+ Tconv cells from OX40/CD30 dKO mice to 
produce IFNγ is abrogated. This was also confirmed by studying another 
endogenous T cell population which recognise peptide 190-201 of Listeriolysin O 
(LLO), a major virulence factor of Listeria monocytogenes (Hamon et al., 2012). 




function, which can be separated from any effects on survival. There was also a 
significant reduction in the number of T cells within both populations in OX40/CD30 
dKO mice, consistent with the established role these TNF receptors play in promoting 
the survival of T cells during activation (Croft, 2009). Despite this, the effect was 
much greater on the production of IFNγ, and therefore these data suggest that CD4 T 
cell function, rather than primary expansion is particularly dependent on OX40 and 
CD30. There is thought to be partial redundancy in the signaling pathways used by 
OX40 and CD30, as CD4 T cell responses are significantly more impaired in mice in 
which both TNF receptors are absent (Gaspal et al., 2008, Gaspal et al., 2005). 
Despite this, the effect on IFNγ production by 2W1S+ Tconv cells observed in 
OX40/CD30 dKO mice could be recapitulated in OX40 KO mice. This therefore 
suggests that OX40 plays a key role in CD4 T cell function. 
This study has demonstrated that CD4 T cell function, rather than primary expansion 
is highly dependent on OX40 and CD30. To further investigate the role of these TNF 
receptors, repeated expansion was studied in OX40/CD30 dKO mice, and compared 
to primary expansion. During acute infection, OX40 is expressed for a short window 
of time (Marriott et al., 2014), but during chronic infection its expression is more 
prolonged (Boettler et al., 2012). Strikingly, expansion of 2W1S+ Tconv cells within 
OX40/CD30 dKO mice after infection with Lm-2W1S, followed by two immunisations 
with 2W1S peptide and agonistic anti-DR3 was grossly reduced compared to WT. 
Interestingly, the number of 2W1S+ Tconv cells in OX40/CD30 dKO mice was only 
approximately 3 fold higher after repeated antigen exposure compared to primary 




response to repeated antigen exposure, and this is affected much more than primary 
expansion.  
Therefore, data within this study suggest that the expansion and function of Treg 
cells is partially dependent on OX40 and CD30. Further to this, the data confirms that 
there is a role for OX40 and CD30 in CD4 T cell expansion. However, these data 
show that CD4 T cells from OX40/CD30 dKO mice are fundamentally impaired in 
both their capacity to produce effector cytokines and to expand in response to 














5.0 THE ROLE OF GROUP 3 INNATE LYMPHOID CELLS IN 














Regulatory T cells, like conventional T cells recirculate around the blood and lymph, 
although, interestingly, it has also been shown that Treg cells can be enriched in the 
lymph node nearest their antigen (Lathrop et al., 2008). Treg cells are highly stable 
(Sakaguchi et al., 2013) and are considered to be a continuously activated and highly 
proliferative T cell subset (Fisson et al., 2003, Walker et al., 2003a). The cytokine IL-
2 is a critical survival factor for Treg cells (Malek and Castro, 2010), which express 
high levels of the high affinity subunit of the IL-2 receptor (CD25). Further to this, 
signals through the co-stimulatory receptor CD28 and the T cell Receptor (TCR) have 
been shown to contribute to Treg cell homeostasis (Attridge and Walker, 2014). 
Immature dendritic cells have been proposed as a potential source of TCR and CD28 
stimulation, through presentation of self-antigen (Scheinecker et al., 2002) and low 
levels of CD80/CD86 expression (Bluestone and Abbas, 2003). However, further 
characterisation of the signals required, and the source of such signals is needed to 
fully understand Treg cell homeostasis. 
Interestingly, preliminary data has shown that Treg cells can be found in close 
association with group 3 Innate Lymphoid Cells (ILCs) in the mesenteric lymph node 
(Dr Fiona McConnell, unpublished data), which suggests that these cells interact.  
ILCs are haematopoietic cells with lymphoid morphology but which lack T cell and B 
cell-receptors, as well as molecules expressed by myeloid cells, such as CD11c 
(Spits and Cupedo, 2012). They can be identified by the absence of such markers, 
as well as expression of Interleukin-7 Receptor α (IL-7Rα) (Vonarbourg and 
Diefenbach, 2012). Multiple roles for ILCs within the innate immune system have 




epithelial barrier integrity and tissue repair. Further to this, it is becoming apparent 
that ILCs are able to influence the adaptive immune system (Artis and Spits, 2015).  
ILCs have been categorised into three groups based on the expression of lineage 
defining transcription factors and signature cytokines (Spits et al., 2013), as is shown 
in Figure 5.1. It is interesting to note that these lineage defining transcription factors 
and signature cytokines mirror those of T cell subsets. Th1 cells depend on Tbet and 
express IFNγ; Th2 cells depend on GATA3 and express IL-4 and IL-13; Th17 cells 
depend on RORγt and express IL-17 and/or IL-22 in response to IL-23 (Spits et al., 
2013).  
 
Figure 5.1: Innate lymphoid cell subsets. ILCs can be categorised into three 
groups based on expression of lineage defining transcription factor and signature 
cytokine expression. 
This study will concentrate on group 3 ILCs, which include the Lymphoid Tissue 
Inducer (LTi) cells, which play an essential role in lymph node organogenesis 
(Mebius, 2003). Group 3 ILCs in the adult are often referred to as ILC3s and can be 
further subdivided on the basis of Chemokine Receptor-6 (CCR6) expression. CCR6+ 




the capacity to exhibit plasticity through downregulation of RORγt and upregulation of 
Tbet as well as the natural cytotoxicity receptor NKp46 (Klose et al., 2013). 
ILC3s are primarily found in the gut but also reside in the lymph nodes and spleen 
(Walker et al., 2013). In secondary lymphoid tissue they are located at the interface 
between T and B cell areas, such as the interfollicular regions (Mackley et al., 2015).  
As shown in Figure 5.2, it was in this location that ILC3s, identified as CD3-IL-
7Rα+RORγt+ cells, were found in close association with FOXP3+ Treg cells. It has 
been proposed that in this location, ILC3s provide survival signals to memory T cells 
as they pass through lymphoid tissue as persistence of CD4 memory T cells has 
been shown to be hindered in mice which lack ILC3s (Withers et al., 2012). 
Therefore, it may be that ILC3s in the interfollicular areas of the lymph nodes and 
spleen also provide survival signals to Treg cells as they recirculate.  
 
Figure 5.2: Association between ILC3s and Treg cells. Location of RORγt+ ILCs 
(ILC3s) (identified as CD3-RORγt+IL-7Rα+) within the mesenteric lymph node and 
proximity to regulatory T cells (identified as CD3+ Foxp3+).  High magnification insert 





Interestingly, ILC3s have been shown to express MHC II and to have the ability to 
process and present antigen, but do so in a manner which does not lead to T cell 
proliferation (Hepworth et al., 2013). Further to this, mice which lack MHC II on ILC3s 
exhibit increased CD4 T responses to commensal bacteria, which leads to gut 
inflammation, suggesting that ILC3s limit CD4 T cell responses to commensal 
bacteria in a MHC II-dependent manner (Hepworth et al., 2013). Indeed, it has 
subsequently been shown that presentation of commensal bacteria-derived antigens 
by ILC3s can cause T cell death in a process similar to negative selection in the 
thymus (Hepworth et al., 2015). The ability of ILC3s to present antigen as a 
mechanism of preserving tolerance opens up the possibility that presentation of self-
antigen by ILC3s could be a mechanism by which Treg cells are maintained, 
particularly due to the key role of TCR stimulation in Treg cell homeostasis. In this 
study, the role of ILC3s in Treg cell expansion and survival has been investigated 
using an antigen-specific approach in mice which lack ILC3s (RORγt KO mice). 







Antigen-specific Treg cell expansion in RORt KO mice 
To determine whether ILC3s may be involved in 2W1S+ Treg cell expansion, RORγt 
KO and WT mice were immunised with 100 µg 2W1S peptide and analysed seven 
days later. RORγt KO mice lack lymph nodes (Sun et al., 2000, Kurebayashi et al., 
2000) and it has been suggested that the loss of the lymph node niche may result in 
redistribution of T cells to the spleen (Zhang et al., 2003). Therefore, the spleen was 
compared to the spleen and a pool of lymph nodes from WT mice. Following 
harvesting of tissue, enrichment of 2W1S+ T cells was performed. Strikingly, very few 
2W1S+ Treg cells could be identified in the RORγt KO mice upon immunisation with 
2W1S peptide (Figure 5.3a). The percentage of Treg cells within the 2W1S+ T cell 
population was 20.1-fold lower in the RORγt KO mice than WT (median 0.5% vs 
median 10.7%) (Figure 5.3b). In accordance with this, the number of 2W1S+ Treg 
cells was reduced by 29.8-fold (median 3 vs median 76) (Figure 5.3c), but there was 
not a significant difference in the number of 2W1S+ Tconv cells (Figure 5.3d). This 
therefore argues against simply an impaired 2W1S+ T cell population.  
It has been reported that a proportion of Treg cells express RORγt (Lochner et al., 
2008), without negative impacts on their stability or function (Tartar et al., 2010, Yang 
et al., 2015). Indeed, it is now emerging that Treg cells can upregulate transcription 
factors associated with different T helper responses, tailoring them towards that 
response (Koch et al., 2009, Chaudhry et al., 2009, Zheng et al., 2009). Although 
RORγt+ Treg cells were shown to be in the minority, 2W1S+ Treg cells from WT mice 




percentage of 2W1S+ Treg cells (median 16%) were found to express RORγt (Figure 
5.3e, f), and therefore its absence cannot explain the low number of 2W1S+ Treg 













































































Figure 5.3: Expansion of regulatory T cells by 2W1S peptide is attenuated in 
RORγt KO mice. WT and RORγt KO mice were immunised intravenously with 
2W1S peptide and analysed 7 days later. A pool of spleen and lymph nodes from 
WT mice were compared to spleen from RORγt KO mice. (A) Identification of 
FOXP3- and FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3+ CD44hi2W1S: 
I-Ab+ T cells (Treg cells). (C) Enumeration of FOXP3- CD44hi2W1S: I-Ab+ T cells 
(Tconv cells). (D) Percentage of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). 
(E) Identification of FOXP3 and RORγt expression by CD44hi2W1S: I-Ab+ T cells 
(wildtype mice). Plots are pre-gated on CD44hi2W1S: I-Ab+ CD3+CD4+ 
B220−CD11b− CD11c− cells. (F) Percentage of FOXP3+CD44hi2W1S: I-Ab+ T cells 
(Treg cells) which express RORγt (wildtype mice). Bars show medians, at least 2 
mice analysed per group. (B, C, D, F) Bars show medians. Mann–Whitney test 
**p < 0.01, ns = non-significant. At least 6 mice were pooled per group from three 






























Agonistic anti-DR3 was then used to further expand the 2W1S-specific population in 
RORγt KO mice given the low numbers of 2W1S+ Treg cells. Therefore, RORγt KO 
and WT mice were immunised with 100 µg 2W1S peptide and 10 µg agonistic anti-
DR3. Seven days later the spleen (RORγt KO) or spleen and a pool of lymph nodes 
(WT) were harvested and enrichment of 2W1S+ T cells was performed. As observed 
previously agonistic anti-DR3 was able to increase the number of regulatory and 
conventional 2W1S+ T cells in WT mice. However, the number of 2W1S+ Treg cells 
was again very low, consistent with the original experiment (Figure 4.4a). The 
percentage of Treg cells within the 2W1S+ T cell population was 12.4-fold lower in 
the RORγt KO mice than WT (median 0.9% vs median 11.1%) (Figure 5.4b), and the 
number of 2W1S+ Treg cells was reduced by 41.1-fold (median 6 vs median 234) 
(Figure 5.4c). Again, there was not a statistically significant difference in the number 
of 2W1S+ Tconv cells between RORγt KO mice and WT (Figure 5.4d). It is 
interesting to note, however, that the median number of 2W1S+ Tconv cells in RORγt 
KO mice after 2W1S peptide and agonistic anti-DR3 administration was 3.2-fold 
lower than WT. Although not statistically significant, this may suggest that the effects 
of agonistic anti-DR3 are dependent on RORγt. Together, these data indicate that 
following immunisation there are far fewer 2W1S+ Treg cells in the spleen of RORγt 
KO mice, compared with WT. These data indicate that in the absence of ILC3s Treg 
cell expansion is impaired. However, it is important to note that due to the role of 
RORγt in the thymus (Sun et al., 2000) there may be fundamental effects on Treg 












































































  Figure 5.4: Expansion of regulatory T cells by 2W1S peptide and agonistic 
anti-DR3 is attenuated in RORγt KO mice. WT and RORγt KO mice were 
immunised intravenously with 2W1S peptide and agonistic anti-DR3 antibody and 
analysed 7 days later. A pool of spleen and lymph nodes from WT mice were 
compared to spleen from RORγt KO mice. (A) Identification of FOXP3- and 
FOXP3+ CD44hi2W1S: I-Ab+ T cells. Plots are pre-gated on 
CD3+CD4+B220−CD11b−CD11c− cells. (B) Enumeration of FOXP3+ CD44hi2W1S: 
I-Ab+ T cells (Treg cells). (C) Enumeration of FOXP3- CD44hi2W1S: I-Ab+ T cells 
(Tconv cells). (D) Percentage of FOXP3+ CD44hi2W1S: I-Ab+ T cells (Treg cells). 
(B-D) Bars show medians. Mann–Whitney test **p < 0.01, ns = non-significant. At 
least 6 mice were pooled per group from three independent experiments. Tconv = 




The specific defect in 2W1S+ Treg cells may reflect an effect on all Treg cells in 
RORγt KO mice. Therefore, to determine whether the overall Treg cell population is 
affected by the loss of RORγt, spleens were harvested from RORγt KO and WT mice 
and phenotyping took place. The median cellularity of the spleen of RORγt KO mice 
was 2.5-fold higher than WT (Figure 5.5a), consistent with previous studies 
(Kurebayashi et al., 2000). The median number of CD4 T cells was also increased by 
2-fold (Figure 5.5b) and the median number of Treg cells by 2.9-fold (Figure 5.5c). 
In accordance with this, the percentage of Treg cells within the CD4 T cell population 
was significantly increased (1.5-fold; median 12.5% vs median 17.6%) (Figure 5.5d). 





















































Figure 5.5: Overall regulatory T cell numbers are not reduced in RORγt KO 
mice. Cells were isolated from the spleen of naïve RORγt KO and WT mice. 
4x106 cells were antibody stained. (A) Cellularity of the spleen. (B) Enumeration 
of FOXP3- CD4+ T cells (Tconv). (C) Identification of FOXP3+ T cells (Treg cells). 
Plots are pre-gated on CD3+CD4+B220−CD11b− CD11c− cells. (D) Enumeration of 
FOXP3+ CD4+ T cells (Treg cells). (E) Percentage of FOXP3+ CD4+ T cells (Treg 
cells). (A-B, D-E) Bars show medians. Mann–Whitney test, **p < 0.01, ***p < 
0.001. At least 8 mice were pooled from two independent experiments. Tconv = 




Treg cell development in RORγt KO mice 
As RORγt is involved in T cell development in the thymus (Sun et al., 2000) it is 
important to investigate whether the defects seen in the 2W1S+ Treg cell population 
reflect fundamental alterations to Treg cell generation in the thymus. Thymocytes can 
be separated into four populations on the expression of CD4 and CD8 (Borgulya et 
al., 1991). Thymocytes enter the thymus as Double Negative (DN) cells, mature into 
Double Positive (DP) cells and undergo positive selection. If successful, DP cells 
then become Single Positive (SP) 4 or 8 cells and undergo negative selection in the 
medulla. RORγt is expressed by DP thymocytes, within which it facilitates survival via 
production of Bcl-xL (Sun et al., 2000). This is thought to give these cells an 
opportunity to interact with MHC II/peptide and if appropriate, go through positive 
selection. As a result, Vα to Jα recombination has been shown to be altered in RORγt 
KO mice (Guo et al., 2002).  
Initially, phenotyping of the thymus of RORγt KO mice was performed to investigate 
whether Treg cell development was impaired in the absence of RORγt. The median 
cellularity of the thymus from these mice was 6.4-fold lower than that of the WT mice 
(Figure 5.6a), which is consistent with previous studies (Sun et al., 2000). This 
reduction was reflected in all thymocyte populations, particularly the SP4 population. 
The median number of SP4 cells was reduced by 42.2-fold and the median number 
of cells in the SP8 population was reduced by 11.3-fold (Figure 5.6b). The dramatic 
reduction in the SP4 population in RORγt KO mice is also displayed in Figure 5.6c, 
which demonstrates the gating strategy for the four thymocyte populations. Within the 
SP4 population, the median number of Treg cells was reduced by 25.4-fold in RORγt 




than the rest of the SP4 population. Consistent with this, the percentage of Treg cells 
within the SP4 population was not significantly different in RORγt KO mice compared 



























Gated on live cells 
























Figure 5.6: Regulatory T cell development is not disproportionally affected 
by the absence of RORγt. Cells were isolated from the thymus of naïve RORγt 
KO and WT mice. 4x106 cells were antibody stained. (A) T cell profile in RORγt 
KO thymus. Plots are gated on live cells. (B)  Cellularity of the thymus. (C) 
Enumeration of Double Negative (DN), Double Positive (DP), Single Positive CD4 
(SP4) and Single Positive CD8 (SP8) cells. (D) Number of FOXP3+ cells (Treg 
cells). (E) Percentage of FOXP3+ cells (Treg cells) within the SP4 population. (B, 
E) Bars show medians. Mann–Whitney test, ***p < 0.001, ns = non-significant. (C) 
Means ± SEM are shown. At least 8 mice were pooled per group from two 




Although total Treg cells were not disproportionally impaired in RORγt KO mice, such 
studies may not identify changes in Treg cell selection in the thymus. Therefore, 
numbers of 2W1S+ Treg cells may still be reduced. To investigate this, the 2W1S+ T 
cell population was assessed in naïve WT and RORγt KO mice. Given concerns over 
low numbers, FOXP3GFP reporter mice were used to optimise the yield of 2W1S+ T 
cells, which are rare. The spleens were harvested from naïve RORγt KO FOXP3GFP 
mice and the spleen and lymph nodes were harvested from naïve FOXP3GFP mice, 
which served as the WT controls. Tetramer staining and enrichment was then 
performed. For each sample, the cells were pooled from two mice after enrichment to 
increase the number of 2W1S+ T cells. Conventional 2W1S+ T cells could be 
identified in RORγt KO mice (Figure 5.7a), although the median number was 2.3-fold 
lower than WT (Figure 5.7b). Similarly, regulatory 2W1S+ T cells were identified in 
RORγt KO mice (Figure 5.7c) and the median number was 3.2-fold lower than WT 
(Figure 5.7d). Although there was a modest reduction in the median number of 
2W1S+ Treg cells, this reflects a reduction in the overall 2W1S-specific T cell 
population, and fundamentally 2W1S+ Treg cells could be identified. This suggests 
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Figure 5.7: 2W1S+ Treg cells can develop in mice which are deficient in 
RORγt. (A) Identification of 2W1S: I-Ab+ T cells in naïve FOXP3 GFP mice and 
RORγt KO x FOXP3GFP mice. Plots are from two mice combined and are pre-
gated on CD3+CD4+B220−CD11b−CD11c− cells. (B) Identification of FOXP3- and 
FOXP3+ 2W1S: I-Ab+ T cells in naïve FOXP3GFP mice and RORγt KO x 
FOXP3GFP mice. Plots are from two mice combined and are pre-gated on 2W1S: 
I-Ab+ CD3+CD4+ B220−CD11b−CD11c− cells. (C) Enumeration of FOXP3- 2W1S: I-
Ab+ T cells. (D) Enumeration of FOXP3+ 2W1S: I-Ab+ T cells. (C, D) Bars show 
medians. Mann–Whitney test, *p < 0.05. At least 4 samples, each from two mice, 




DR3 expression on Innate Lymphoid cells 
Previous data from Figure 5.4 indicated that the effect of agonistic anti-DR3 on Treg 
cell numbers is reduced in RORγt KO mice. Interestingly along with regulatory and 
conventional T cells, embryonic LTi, which are part of the group 3 ILC subset, have 
been shown to express DR3 (Kim et al., 2003). Further to this, DR3 expression has 
been shown on adult cells which resemble these embryonic cells (Kim et al., 2003), 
now classified as ILC3s. ILC populations are known to differ between different lymph 
nodes (Mackley et al., 2015), therefore DR3 was stained for in inguinal lymph nodes, 
mesenteric lymph nodes and spleen. These tissues were harvested from naïve mice, 
teased under a microscope and digested using collagenase dispase and DNase prior 
to staining to increase the yield of cells. ILCs were identified by flow cytometry as IL-
7Rα+ cells lacking lineage markers associated with T cells, B cells and myeloid cells. 
To ensure that T cells were not included in this population, cells which contained 
intracellular CD3 were gated out. The three ILC populations were then separated into 
RORγt+ (ILC3s), GATA-3+ (ILC2s) and the double negative population (ILC1s) 
(Figure 5.8). This method of staining enables clear gating of ILC3s and enables 





























Figure 5.8: Gating strategy for ILC Subsets. Cells were isolated from the 
spleen, mesenteric lymph node and inguinal lymph nodes of C57BL/6 mice. Cells 
were surface stained, fixed, permeabilised and analysed by flow cytometry. 
Gating strategy for ILCs and for ILC subsets: ILC1 (RORγt- GATA3-), ILC2 




As previously described, adult ILC3s can be divided into two subsets based on CCR6 
expression (Klose et al., 2014). The CCR6+ (LTi-like) ILC3s are of principal interest 
within this study, and make up the majority of ILC3 population in the mesenteric 
lymph node (Mackley et al., 2015). Thus CCR6 can be used as a surrogate marker to 
identify ILC3s in place of RORγt, as shown in Figure 5.9a. This surrogate marker 
was used when validating the anti-DR3 antibody using DR3 KO mice, as the anti 
DR3 antibody was conjugated to the same fluorochrome as the anti-RORγt antibody 
(Figure 5.9b).  As shown in Figure 5.9c, DR3 could be identified on all three subsets 
of ILCs. In all three tissues, the majority of ILC3s were found to express DR3 
(medians 94-98%) (Figure 5.9d). Similarly, the majority of ILC2s expressed DR3 in 
the lymph nodes (medians 95-99%) and the spleen (median 85%) (Figure 5.9e). A 
high percentage of ILC1s in the lymph nodes expressed DR3 (medians 75-79%), and 
approximately half of IL1s in the spleen (median 50%) (Figure 5.9f). Therefore, the 
majority of ILC3s express DR3 in peripheral and mesenteric lymph nodes, as well as 
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Figure 5.9: DR3 is highly expressed by ILC3s. Cells were isolated from the 
spleen, mesenteric lymph node and inguinal lymph nodes of C57BL/6 mice. Cells 
were surface stained, fixed, permeabilised and analysed by flow cytometry. (A) 
(B). (C) Identification of DR3 on ILC subsets from spleen, mesenteric lymph 
nodes and inguinal lymph nodes. (D) Percentage of each ILC subset which 
expresses DR3 in each lymphoid organ analysed. Bars show medians. At least 














































Determining potential interaction partners between Treg cells and Innate Lymphoid 
Cells 
Impaired Treg responses have been observed in RORγt KO mice within this study, 
which suggests that Treg cells may interact with ILC3s. This is consistent with 
preliminary data which shows that ILC3s can be found in close association with Treg 
cells in the interfollicular areas of the mesenteric lymph node (Figure 5.1). In this 
study, the expression of potential interaction partners between ILC3s and Treg cells 
has been explored to further investigate this. These include Neuropilin-1 (Nrp-1), 
which has been shown to enhance Treg cell stability (Delgoffe et al., 2013) and can 
signal through homotypic interactions (Sarris et al., 2008);  and MHC II as Treg cell 
homeostasis is known to be supported by encounter with cognate antigen (Attridge 
and Walker, 2014). Further to this, there is thought to be a switch in the function of 
group 3 ILC3s from lymph node organogenesis in the embryo, to modulation of the 
adaptive immune system, as well as roles in the innate immune system, in the adult 
(Kim et al., 2006). This study therefore also investigated whether MHC II is 
expressed on group 3 ILCs in the embryo (LTi), and hence this functional switch. 
To identify Nrp-1 expression, the inguinal lymph nodes, mesenteric lymph nodes and 
spleen were harvested from naïve mice, teased under a microscope and digested 
using collagenase dispase and DNase. The three ILC subsets were gated upon 
using the previously strategy. ILC3s were found to be the predominant Nrp-1 
expressing subset of ILCs (Figure 5.10a). There was little Nrp-1 on ILC1s in all three 
tissues (Figure 5.10b). A proportion of ILC2s in the spleen and mesenteric lymph 
nodes expressed Nrp-1 (medians 33-41%), but there was little expression in the 




majority of ILC3s were found to express Nrp-1 (medians 85-89%), and approximately 
half of the ILC3s inguinal lymph nodes (median 53%) (Figure 5.10d). To confirm 
these data, confocal microscopy was used. ILC3s were identified in the interfollicular 
areas of mesenteric lymph node sections as IL-7Rα+ RORγt+ CD3- cells. Figure 
5.10e shows a magnification of the interfollicular area (marked by a white box). Nrp-1 
positive ILC3s can be identified in this area, and have been circled in white. The 
panel on the right allows confirmation that these cells are not CD3+. This 
demonstrates that the majority of ILC3s in the mesenteric lymph nodes express Nrp-
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Figure 5.10: Neuropilin-1 is highly expressed by ILC3s. (A-B) Cells were 
isolated from the spleen, mesenteric lymph node and inguinal lymph nodes of 
C57BL/6 mice. Cells were surface stained, fixed, permeabilised and analysed by 
flow cytometry. (A) Identification of Neuropilin-1 (Nrp-1) on ILC subsets from 
spleen, mesenteric lymph nodes and inguinal lymph nodes. Gating of ILC 
subsets was performed as shown previously. (B) Percentage of each ILC subset 
which expresses Nrp-1 in each lymphoid organ analysed. Bars show medians. At 
least four mice were pooled from two independent experiments. (C) Mesenteric 
lymph node sections from naïve wildtype mice were cut and stained for Nrp-1 on 
ILC3s. Interfollicular area (white box) of image on left is magnified with and 
without Nrp-1 on right. F indicates follicle. ILC3s are identified as IL-7Rα+ RORγt+ 









To identify MHC II expression, the inguinal lymph nodes, mesenteric lymph nodes 
and spleen were harvested from naïve mice, teased under a microscope and 
digested using collagenase dispase and DNase. The three ILC subsets were gated 
upon using the strategy previously shown. In the mesenteric lymph nodes and 
spleen, ILC3s were the only ILC population which expressed MHC II (Figure 5.11a).  
In the inguinal lymph nodes, however, MHC II expression was observed by all three 
groups of ILCs. In these peripheral lymph nodes, the median percentage of ILC1s 
expressing MHC II was 38% (Figure 5.11b) and the median percentage of MHC II+ 
ILC2s was 63% (Figure 5.11c). In all three tissues, MHC II expression was observed 
on a high proportion of ILC3s (medians 67-79%) (Figure 5.11d). To confirm these 
data, confocal microscopy was used. ILC3s were again identified in the interfollicular 
areas of mesenteric lymph node sections as IL-7Rα+ RORγt+ CD3- cells. Figure 
5.11e shows a magnification of the interfollicular area (marked by a white box). MHC 
II positive ILC3s can be identified in this area, and have been circled in white. The 
panel on the right allows confirmation that these cells are not CD3+. Therefore, the 
majority of ILC3s express MHC II in the mesenteric lymph nodes. Together these 
data show that MHC II expression is observed by ILC3s in peripheral and mesenteric 
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Figure 5.11: MHC II is highly expressed by ILC3s. (A-B) Cells were isolated 
from the spleen, mesenteric lymph node and inguinal lymph nodes of C57BL/6 
mice. (A) Identification of MHC II on ILC subsets from spleen, mesenteric lymph 
nodes and inguinal lymph nodes. Gating of ILC subsets was performed as shown 
previously. (B) Percentage of each ILC subset which expresses MHC II in each 
lymphoid organ analysed. Bars show medians. At least four mice were pooled 
from two independent experiments. (C) Mesenteric lymph node sections from 
naïve wildtype mice were cut and stained for MHC II on ILC3s. Interfollicular area 
(white box) of image on left is magnified with and without MHC II on right. F 
indicates follicle. ILC3s are identified as IL-7Rα+ RORγt+ CD3- cells. White circles 




The ligand for DR3, TL1A, has been shown to induce OX40L expression on LTi cells 
upon overnight culture (Kim et al., 2006). OX40L is expressed by adult ILC3s but not 
embryonic LTi (Kim et al., 2005) and therefore this is thought to be part of this 
developmental switch from embryonic to adult cells (Kim et al., 2006). MHC II has 
also been shown to be expressed by adult ILC3s (Hepworth et al., 2013) and may 
follow the same TL1A-induced developmental switch. To investigate this, spleens 
were removed from E15 embryos and cultured for seven days with IL-7 to increase 
the number of LTi cells. Spleens then were pooled into groups of six, teased under a 
microscope and crushed to create cell suspensions. Cells were cultured overnight 
with IL-7 +/- 100ng/ml TL1A in accordance with the original experiments showing that 
TL1A can upregulate OX40L (Kim et al., 2006). A cell suspension was cultured with 
10 µg/ml agonistic anti-DR3 instead of TL1A to determine whether the antibody can 
recapitulate the effects of this soluble mediator.  
As shown in Figure 5.12a, LTi cells were identified simply as RORγt+ cells. This is 
possible because LTi cells are the major RORγt-expressing population at E15 (Eberl 
et al., 2004). There was little OX40L or MHC II expression on LTi which were cultured 
with IL-7, which confirms previous observations that embryonic LTi do not express 
these molecules. Upon TL1A administration OX40L was upregulated on LTi (median 
31%), but the levels of MHC II remained unchanged (Figure 5.12b). This effect of 
TL1A on OX40L expression was therefore consistent with previously published data 
(Kim et al., 2006) and amounted to a 31.1-fold increase in the median percentage of 
LTi which expressed OX40L (Figure 5.12c). Upon treatment with agonistic anti-DR3 
a small proportion of LTi were found to express OX40L (median 13%) (Figure 




lesser extent than TL1A. MHC II expression was again unchanged. Therefore, MHC 
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  Figure 5.12: Expression of MHC II is not regulated by DR3 signaling. E15 
BALB/c embryonic spleens were placed on a sterile nucleopore filter laid on a 
piece of sterile antiwrap sponge (6 spleens per filter). These were placed in 4ml 
sterile culture medium containing IL-7 and cultured for 6-7 days at 37°C in a 
sterile humidified chamber. Cells were then isolated and cultured overnight with 
IL-7 +/- TL1A or agonistic anti-DR3. On the next day cells were stained for dead 
cells prior to antibody staining. (A) Gating strategy for LTi. (B) Identification of 
OX40L and MHC II on LTi. (C) Percentage of LTi which express OX40L. (D) 
Percentage of LTi which express MHC II. (A-B) Plots are representative of three 
independent experiments. Six spleens were pooled for each condition. Bars show 




These data therefore show that Nrp-1 and MHC II are expressed by ILC3s in the 
periphery. Future study into the relationship between Treg cells and ILC3s may be 
facilitated by the ability to boost ILC3 numbers. The administration of IL-2/anti-IL-2 
complexes has been shown to cause ILC2 proliferation (Van Gool et al., 2014). 
Interestingly, this is also a technique which has been used to boost Treg cells 
(Webster et al., 2009). To investigate whether IL-2/anti-IL-2 complexes can also 
induce ILC3 proliferation, WT mice were administered complexes composed of 1 µg 
IL-2 and 5 µg anti-IL-2, or PBS as a control, by intraperitoneal injection for three 
days. The mesenteric lymph node and spleen were then harvested the day after the 
final injection. ILC3s were identified as previously shown, and expression of Ki67 was 
used to identify proliferating ILC3s. As shown in Figure 5.13a, ILC3s from PBS 
injected mice displayed little Ki67 expression, but upon administration of IL-2/anti-IL-
2 complexes, Ki67 expression was induced on these cells. In the mesenteric lymph 
nodes, the percentage of Ki67+ ILC3s was found to be 13.7-fold higher in the IL-
2/anti-IL-2 complex-injected mice than the PBS-injected mice (median 54.4% vs 
median 3.9%) (Figure 5.13b). At this early time point a 1.6-fold increase in ILC3 
number could also be observed (median 6503 vs median 10062) (Figure 5.13c). In 
the spleen, the percentage of Ki67+ ILC3s was 3.9-fold higher in the IL-2/anti-IL-2 
complex-injected mice than the PBS-injected mice (median 44.7% vs median 11.6%) 
(Figure 5.13d). As observed in the mesenteric lymph node, a 1.3-fold increase in 
ILC3 number was observed in the spleen (median 15849 vs median 20611) (Figure 
5.13e). Therefore, administration of IL-2/anti-IL-2 complexes can be used 
successfully to induce ILC3 proliferation, although later time points will need to be 




















































  Figure 5.13: ILC3s proliferate in response to IL-2/anti-IL2 complexes. IL-
2/anti-IL-2 complexes were administered to WT mice by intraperitoneal injection 
for three days and the mesenteric lymph node and spleen were analysed on the 
fourth day. (A) Identification of Ki-67 expression on ILC3s from the mesenteric 
lymph nodes and spleen. Gating of ILC3s was performed as shown previously. 
(B) Percentage of ILC3s which express Ki67 in the mesenteric lymph nodes. (C) 
Enumeration of ILC3s in the mesenteric lymph nodes. (D) Percentage of ILC3s 
which express Ki67. (E) Enumeration of ILC3s in the spleen. (B-D) Bars show 
medians. Mann–Whitney test **p < 0.01, ns = non-significant. At least six mice 





Therapeutic manipulation of Treg cell survival, as well as function, would have far 
reaching implications in a range of conditions from cancer to autoimmune disease. 
However, the cells and signals which are required for Treg cell homeostasis are yet 
to be fully elucidated. It has been proposed that low level CD80 and CD86 
expression on immature dendritic cells, as well as presentation of self-antigen, may 
promote Treg survival, through CD28 and TCR signals. Interestingly ILC3s have also 
been shown to have the capacity to process and present antigen (von Burg et al., 
2014, Hepworth et al., 2013). Therefore, within this study, the role of this ILC subset 
in Treg cell biology was investigated in RORγt KO mice, which lack ILC3s. An 
antigen-specific approach was again used so that the timing and nature of antigen 
exposure was known. 
Using an antigen-specific approach, Treg cells can be expanded and tracked over an 
extended period of time to understand the signals necessary for their survival. 
However, within this study, very few 2W1S+ Treg cells could be identified in RORγt 
KO mice seven days after immunisation with 2W1S peptide. This impairment was 
more restricted to the regulatory population, with few differences observed in the 
number of Tconv cells between WT and RORγt KO mice. This impairment in 2W1S+ 
Treg cell expansion was also observed seven days after immunisation with 2W1S 
peptide and agonistic anti-DR3, which has been shown previously in this study to 
enhance the number of regulatory and conventional T cells within the 2W1S+ T cell 
response. These data therefore suggest that the expansion of regulatory, but not 
conventional 2W1S+ T cells is RORγt-dependant.  The signals required for Treg cell 




T cell activation. Treg cells are activated in an antigen specific manner, requiring 
stimulation through their TCR (Thornton et al., 2004a, Thornton et al., 2004b). It is 
possible that ILC3s, through expression of MHC II, could contribute to Treg cells 
activation, although they lack expression of CD80/86 ligands, and therefore the 
capacity for CD28 signaling (Hepworth et al., 2013), which has been shown to be 
important for Treg cell proliferation (Bour-Jordan et al., 2011). 
To determine whether this impairment in Treg cell expansion is reflected in the 
overall Treg population, the spleen of naïve RORγt KO mice was studied. However, 
the number and percentage of Treg cells was increased RORγt KO mouse, which is 
not consistent with impaired Treg cell expansion. It is notable that RORγt KO mice do 
not have lymph nodes (Kurebayashi et al., 2000, Sun et al., 2000) and the spleen of 
RORγt KO mice is more than twice the size of WT, with significantly higher numbers 
of conventional and regulatory CD4 T cells. Due to the previously described role of 
ILC3s in the gut, a key reason for the enlargement of the spleen in RORγt KO mice is 
thought to be due to inflammation in response to commensal bacteria (Hepworth et 
al., 2013). The presence of compounding factors such as this demonstrates the 
importance of using an antigen-specific approach. It is important to note also that 
RORγt has an important role in thymocyte development, and therefore there is a 
possibility that the absence of 2W1S+ Treg cells in RORγt KO mice could be due to 
altered Treg cell selection. In the thymus, RORγt facilitates the survival of double 
positive thymocytes via production of Bcl-xL (Sun et al., 2000). This is thought to give 
these cells an opportunity to interact with MHC II/peptide and if appropriate, go 
through positive selection. Vα to Jα recombination has been shown to be altered in 




TCRα repertoire. It was therefore important to investigate whether Treg cell 
development is adversely affected in the RORγt KO thymus. Consistent with 
previously published data, the single positive 4 (SP4) and single positive 8 (SP8) 
populations were dramatically reduced in the RORγt KO mouse. However, Treg cells 
did not appear to be more affected than the rest of the SP4 population. Crucially, 
2W1S+ Treg cells were identified in the periphery of naïve RORγt deficient mice, 
suggesting that these mice 2W1S+ Treg cells can develop in the RORγt KO thymus. 
Therefore, the specific impairment in Treg cell expansion in RORγt KO is not due to 
the absence of 2W1S+ Treg cell generation in these mice. A model in which ILC3s 
are specifically depleted, is necessary to confirm that it is the absence of ILC3s which 
leads to the defect observed.  
Interestingly, the expansion of 2W1S+ Tconv cells upon administration of 2W1S 
peptide and agonistic anti-DR3, but not 2W1S peptide alone, was reduced in RORγt 
KO mice. As the majority of ILC3s in the spleen, inguinal and mesenteric lymph 
nodes were found to express DR3 in this study; there may be a role for ILC3s in the 
action of this agonistic anti-DR3 antibody. Interestingly the majority of ILC2s also 
expressed DR3, and this TNF receptor has been shown to be important for ILC2 
expansion, survival and function (Yu et al., 2014). The high level of DR3 expression 
on ILC3s suggests that DR3 has an important role on these cells, and further 
investigation is needed to determine if there are any parallels with the role on ILC2s. 
As previously introduced, group 3 ILCs include LTi, which are required for lymph 
node organogenesis. DR3 is also expressed by LTi (Kim et al., 2006) and 
interestingly, its ligand TL1A has been shown to induce OX40L expression on LTi 




reflect the change in function of group 3 ILCs from lymph node organogenesis to 
their roles within the immune system, and corresponds with bacterial colonisation 
which occurs upon birth. It is possible that MHC II, which is expressed by ILC3s in 
the adult (Hepworth et al., 2013) is subject to this same developmental switch 
mediated by TL1A-DR3 interactions. Data within this study showed that like OX40L, 
MHC II is not expressed by embryonic LTi. However, as MHC II was not upregulated 
upon culture with TL1A, it appears that MHC II is regulated by another mechanism. 
This impairment of Treg cell expansion along with observations from preliminary 
data, suggest that Treg cells and ILC3s do indeed interact. Various candidates have 
emerged as potential interaction partners between ILC3s and Treg cells. This study 
has previously explored the role of OX40 and CD30 on Treg cell expansion, survival 
and function, as OX40L and CD30L are expressed by ILC3s (Lane et al., 2005). 
Another molecule expressed by Treg cells which has been proposed to support their 
survival is neuropilin-1 (Nrp-1) (Delgoffe et al., 2013), which is also a proposed 
marker of thymically derived Treg cells (Weiss et al., 2012, Yadav et al., 2012). 
These effects on Treg cell stability are reported to be through interactions with 
Semaphorin-4a (Delgoffe et al., 2013), but Nrp-1 has also been shown to signal 
through homotypic interactions to promote long interactions and therefore synapse 
formations between Treg cells and immature dendritic cells (Sarris et al., 2008). 
Interestingly Nrp-1 is expressed by the majority of ILC3s in the periphery, which 
leaves open the possibility that homotypic interactions between Nrp-1 on Treg cells 
and ILC3s may support their stability. Confocal microscopy has revealed that the 




this is where ILC3s reside, this gives further evidence that homotypic Nrp-1-Nrp-1 
interactions may occur. 
MHC II was shown to be expressed on the majority of ILC3s in the periphery. As Treg 
cell homeostasis is known to be supported by encounter with cognate antigen (Kim et 
al., 2009, Walker et al., 2003a, Fisson et al., 2003), this may be the role of ILC3-
derived MHC II in the periphery. Notably, a similar role has already been proposed 
for dendritic cells in non-inflammatory conditions (Scheinecker et al., 2002). 
Interestingly, ILC3s in the gut have been shown to maintain tolerance to commensal 
through antigen presentation resulting in T cell anergy and death (Hepworth et al., 
2015, Hepworth et al., 2013). Thus a regulatory role for MHC II-expressing ILC3s, 
through interactions with T cells, has been proposed, which may also translate to the 
periphery.  
These data show that in the absence of ILC3s, Treg cell expansion is impaired. 
Studies using mice in which ILC3s are specifically depleted are needed to investigate 
further and confirm that this defect is due to the absence of ILC3s. However, along 
with the observation that ILC3s and Treg cells can be found in close association 
interfollicular areas of lymph nodes, these data suggest that ILC3s and Treg cells 
interact. The use of IL-2/anti-IL-2 complexes to expand ILC3 numbers will also aid 
future understanding of the relationship between ILC3s and Treg cells; an approach 
which was further developed within this study. Nrp-1 has emerged as a strong 
candidate for mediating the interactions between ILC3s and Treg cells, as well as 
presentation of peptide to Treg cells by MHC II on ILC3s. As DR3 is so highly 
expressed on ILC3s, and has been shown to be important for ILC2 biology, this TNF 



























Treg cells are a subset of CD4 T cells which have an important role in maintaining 
tolerance to self-antigens, and provide feedback control to the immune system to 
limit pathogen-associated immune pathology (Corthay, 2009). Treg cells can 
suppress many different immune cells, but their main function is considered to be 
suppression of naïve T cell activation (Schmidt et al., 2012). Since their discovery 
(Gershon and Kondo, 1970, Sakaguchi et al., 1995) there has been great interest in 
the therapeutic potential of Treg cell manipulation. There are many situations in 
which boosting Treg cell activation, survival or function would be beneficial, such as 
autoimmune disease, allergy and transplantation. Conversely, inhibition of Treg cells 
would boost anti-tumour responses and therefore aid tumour clearance by the 
immune system. Current advances in anti-tumour immunotherapy have included 
strategies to release effector T cells from regulation, for example by blocking CTLA-4 
and PD-1 (Curran et al., 2010). However, it is hoped that agonistic antibodies 
directed against TNF receptors would have dual anti-tumour effects by turning off 
Treg cell function as well as boosting effector T cell activation through co-stimulation 
(Kitamura et al., 2009). To better study Treg cell survival and function, and hence the 
cells and signals required, an in vivo antigen-specific approach was developed to 
allow specific effects on survival versus function to be dissected out. 
Therefore, in this study the following aims were addressed: 
 Establish a method to study Treg cell survival and function in vivo. 
 Investigate the sources of cellular support, and the role of TNF receptors in 




6.1 Development of an antigen-specific model to study regulatory T cells 
In this study, an antigen-specific approach pioneered by Dr Marc Jenkins was refined 
specifically to study Treg cells. Using this in vivo approach, an endogenous naïve 
CD4 T cell population is expanded upon encounter with 2W1S peptide, a variant of 
peptide 52-68 of the I-E alpha chain, and identified using MHC II tetramers. Studying 
endogenous murine polyclonal populations of CD4 T cells avoids potential artefacts 
arising from monoclonal TCR transgenic cells, such as reported detrimental effects 
on survival of having a large clonal population (Hataye et al., 2006). To specifically 
study Treg cells within this CD4 T cell population, approaches used to expand overall 
Treg cells were applied to the 2W1S model.  
After immunisation with 2W1S peptide, Treg cells were found to make up 
approximately 13% of the 2W1S+ T cell population. However, by immunising twice 
with 2W1S peptide, seven days apart, this percentage could be boosted, through a 
selective increase in the number of 2W1S+ Treg cells. This observation may have 
important implications in terms of autoantigen-specific immunotherapy for 
autoimmune disease, where the challenge is to boost Treg cells specific to an 
autoantigen, without exacerbating the effector response. As well as exploring 
methods to increase the proportion of antigen-specific Treg cells it was also 
important to ensure a high number of these cells could be expanded, for example to 
boost efforts to assess long term survival, where low numbers might hinder assay 
sensitivity. In this study it was found that an agonistic antibody which targets the TNF 
receptor DR3 can increase the number of Treg cells within this population by 
approximately ten fold, although it also increases the number of Tconv cells and 




increases the percentage of total Treg cells, and such disparity is thought to be a 
result of relative availability of cognate antigen (Schreiber and Podack, 2013). 
Therefore, after 2W1S peptide administration, expansion of regulatory and 
conventional T cells which recognise this peptide occurs, as well as total Treg cells 
which are encountering self-antigen. The protocol for expanding Treg cells was 
therefore set as two immunisations of 2W1S peptide and agonistic anti-DR3, hence 
incorporating both an increase in proportion, and number.  
To study Treg cell function in vivo, an assay was established based on work by Rowe 
et al. (2012), in which the function of 2W1S+ Treg cells was assessed through 
measurement of IFNγ production by 2W1S+ Tconv cells upon infection with Listeria 
monocytogenes-expressing 2W1S peptide (Lm-2W1S). In these experiments 2W1S+ 
Treg cells were expanded in response to constitutive expression of 2W1S peptide as 
a fetal antigen, and peaked at 50% of the 2W1S+ T cell population. In my study, 
2W1S+ Treg cells were expanded using two immunisations of 2W1S peptide and 
agonistic anti-DR3, which resulted in blunting of a subsequent T cell response to Lm-
2W1S. Although IFNγ production was not affected, blunting of the response is 
consistent with Treg cell mediated suppression.  
Interestingly, this study showed that if Lm-2W1S is administered prior to the protocol 
for expanding Treg cells, a very large expansion of 2W1S+ Tconv cells occurs despite 
the presence of 2W1S+ Treg cells. This suggests that suppression is harder to 
achieve after a strong Th1 response. One proposed avenue to prevent destruction of 
tissue in autoimmune disease is Treg cell expansion (Miyara et al., 2014), however 
this may be technically challenging if these findings are confirmed, as clinical 




observation may reflect differences in the ratio of Treg cells to effector cells, as after 
Lm-2W1S administration the percentage of Treg cells is very low. Alternatively, it may 
reflect enhanced resistance of effector cells to Treg cell-mediated suppression. 
Indeed, it has been reported that high doses of antigen can render T cells resistant to 
suppression (Baecher-Allan et al., 2002, Georger et al., 2003), and a role for 
PAMPS, pro-inflammatory cytokines and TNF receptors has also been reported 
(Walker, 2009).  
6.2 The role of OX40 and CD30 in regulatory and effector T cell biology 
The role of OX40 signaling in Treg cell biology is controversial within the literature, 
with reports that OX40 negatively regulates Treg cell function, and conversely that 
OX40 and IL-2 signal co-operatively to support Treg cells (Xiao et al., 2012). Having 
established a model to assess Treg cells, I sought to study the role of TNF receptors 
OX40 and CD30 in in this context. Interestingly, primary expansion of Treg cells was 
impaired in OX40/CD30 dKO mice, although less so than Tconv cell expansion. 
However, a decline in Treg cell numbers was not clearly observed at 21 or 51 days 
after immunisation suggesting longer term survival of Treg cells in the periphery is 
not highly dependent on OX40 and CD30. Data within this study and others strongly 
indicates that the majority of 2W1S+ Treg cells are thymically derived (tTreg cells). 
Therefore, the observed impairment in Treg cell expansion is unlikely to be explained 
by effects on the Tconv cell pool. There are two proposed markers of tTreg cells, 
Neuropilin-1 and Helios, which along with the presence of a Treg cell population in 
naïve mice, give a strong indication of the origin of a Treg cell population. However, 
the field would benefit from the characterisation of a more robust marker for tTreg 




al., 2015). This would aid understanding of the differing roles of these the two 
subsets which are thought to have non-overlapping functions but to synergise to 
attain maximal suppression (Haribhai et al., 2011a). Collectively these data showed 
that following peptide stimulation the persistence of Treg cells was not heavily 
dependent upon signals through CD30 and OX40. Whist the cells persisted, whether 
these cells remained functional became the key question to address. 
The previously described in vivo assay developed to assess Treg cell function was 
used to investigate the role of OX40 and CD30. Blunting of the response was again 
observed in the wildtype control mice, but interestingly, this was not observed in 
OX40/CD30 dKO mice, consistent with an impairment of the function of Treg cells in 
the absence of these signals. These data therefore support the body of evidence that 
OX40 signaling supports Treg cells. Further experiments in mice which can be 
conditionally depleted of Treg cells are needed to confirm that the impairment in the 
response to Lm-2W1S after Treg cell expansion is indeed dependent on the 
presence of Treg cells. The most effective model for studying this would be to use 
‘FOXP3DTR’ mice, which are engineered so that the Diphtheria Toxin Receptor (DTR) 
is expressed by Treg cells, and therefore these cells can be specifically ablated by 
administration of Diphtheria Toxin (Kim et al., 2007).  
This study has also furthered our understanding of the role of OX40 and CD30 in 
CD4 T cell function. Strikingly, CD4 T cells were found to be highly dependent on 
OX40 and CD30 as the ability of antigen-specific Tconv cells to produce IFNγ in 
response to Lm-2W1S was grossly impaired in their absence. Therefore, this study 
has demonstrated that CD4 T cell function, rather than primary expansion is highly 




cells upon activation, but in acute infection OX40 is only transiently expressed, and 
indeed the majority of OX40 expression is restricted to a brief window after Lm-2W1S 
administration (Marriott et al., 2014). Thus the requirement for OX40 signalling in the 
function of these cells indicates that critical interactions with OX40L+ cells must occur 
within this time. If we can pinpoint the cellular source of OX40L, we can better 
manipulate the process therapeutically.  
Importantly, the requirement for OX40 and CD30 signals in CD4 T cell function was 
not restricted to the 2W1S response, and could be observed in another endogenous 
T cell population which responds to Listeriolysin-O, a major virulence factor of Listeria 
monocytogenes (Hamon et al., 2012). Thus, these data indicate that there is a clear 
requirement for OX40 in the production of effector cytokines in Th1 responses such 
as the response mounted to Lm-2W1S. Further experiments in other experimental 
settings could test whether it is true of other T helper responses, for example using 
Group A Streptococcus expressing 2W1S peptide (GAS-2W1S) would enable the 
study of Th17 responses (Dileepan et al., 2011). 
The gross impairment in effector cytokine production by 2W1S+ T cells was also 
observed in OX40 KO mice, which suggests that this effect is largely attributable to 
OX40, although future experiments with CD30 KO mice are required. CD30 is not as 
well characterised in the literature and it is technically challenging to identify CD30 
ex-vivo as it appears to be expressed at low levels. However, it has previously been 
shown that CD4 memory T cell generation in OX40 KO mice is affected by OX40, 
and that this is more pronounced if both receptors are absent, which suggest that 




Gaspal et al., 2011). To further investigate the role of OX40 in CD4 T cell function, 
other pro-inflammatory cytokines could be assessed such as TNFα. 
Interestingly, this study also revealed that OX40 and CD30 are required for CD4 T 
cells to be able to expand in response to repeated antigen exposure, as occurs in 
autoimmunity, as well as many other conditions where therapeutic manipulation of 
the immune response would be beneficial. To further study the contribution of OX40 
and CD30, this experiment should be performed in OX40 KO mice, as well as CD30 
KO mice. Together these data show fundamental differences in CD4 T cell behavior 
in the absence of OX40 and CD30, with reduced rapid pro-inflammatory cytokine 
production, as well as impaired expansion upon repeated antigen exposure. This 
therefore indicates that the capacity to mount functional memory CD4 T cell 
responses is impaired. 
6.3 Cellular support for Treg cell survival 
Previous studies on the cells that support Treg cells has centered mainly on 
immature dendritic cells, which may provide survival signals through the TCR and 
CD28 on Treg cells (Attridge and Walker, 2014). This study has instead explored the 
role of group 3 ILCs, using the previously described antigen-specific approach in 
mice that lack RORγt, the lineage defining transcription factor of this group of ILCs. 
Whilst technically challenging to specifically pinpoint ILC3 due to a lack of specific 
mouse models, the absence of ILC3s correlated with a striking impairment in Treg 
cell expansion. This suggests that these cells may interact, supporting preliminary 
data which showed Treg cells in close proximity to ILC3s in the interfollicular areas of 




of lymph nodes, and altered thymic development (Sun et al., 2000, Kurebayashi et 
al., 2000). However, as 2W1S+ Treg cells can be identified in naïve RORγt KO mice, 
it is possible to conclude that this effect is not simply due to the absence of 2W1S+ 
Treg cell generation in the RORγt KO mice. Studies using mice in which ILC3s are 
specifically depleted are therefore needed to investigate this further and confirm that 
this defect is due to the absence of ILC3s. Interestingly, DR3 was shown to be highly 
expressed on ILC3s in this study, and is therefore likely to have a role in ILC3 
biology, particularly as DR3 expression has been shown to contribute to ILC2 
expansion, survival and function (Yu et al., 2014). 
Various candidates have emerged as potential interaction partners between ILC3s 
and Treg cells. OX40L and CD30L have been reported to be expressed by ILC3s 
(Lane et al., 2005), but Treg cells do not appear to be highly dependent on OX40 and 
CD30 for their survival. This study shows that Nrp-1, which has been proposed to 
support Treg cell survival (Delgoffe et al., 2013), is highly expressed by ILC3s in the 
periphery. As there are reports that Nrp-1 can form homotypic interactions (Sarris et 
al., 2008), this may be a mechanism by which ILC3s support Treg cell survival, 
particularly as the interfollicular area was shown to be rich in Nrp-1 expression. To 
study this further a mouse could be generated which lacks Nrp-1 specifically on 
ILC3s using the cre-lox system, and experiments could be performed to determine 
whether antigen-specific Treg cell survival is affected.   
In this study it was also shown that MHC II is highly expressed by ILC3s in the 
periphery. As TCR signals have been shown to contribute to Treg cell survival (Kim 
et al., 2009, Walker et al., 2003a, Fisson et al., 2003) MHC II may be a potential 




been shown to express high levels of MHC II and to be able to process and present 
antigen (Hepworth et al., 2013). Further studies with these mice, which lack MHC II 
on ILC3s, would aid understanding of whether MHC II on ILC3s provides survival 
signals to Treg cells. Whilst investigating the role of ILC3s in Treg cell survival, it is 
important to note that different lymph nodes contain different proportions of ILC3s 
(Mackley et al., 2015). The use of IL-2/anti-IL-2 complexes to expand ILC3 numbers 
may also aid future understanding of the relationship between ILC3s and Treg cells; 
an approach which was further developed within this study.  
6.4 Overall Summary 
This study has established a method to study the survival and function of Treg cells 
in vivo, and therefore to investigate the signals and cells which are involved. The role 
of ILC3s was explored, as well as the co-stimulatory molecules OX40 and CD30. 
Figure 6.1 shows some of the key signals required by Treg cells, which may be 
provided by dendritic cells, and demonstrates potential roles for ILC3s and 
OX40/CD30 within this context. These experiments provided evidence for a role for 
OX40 and CD30 in Treg cell expansion, as well as function. In addition, effector 
cytokine production by Th1 cells was shown to be heavily dependent upon signals 
through these TNF receptors, as well as their ability to expand upon repeated antigen 
exposure. This therefore indicates that OX40 and CD30 are required to mount 
functional CD4 memory T cell responses. A regulatory role of ILC3s is emerging in 
the literature, and in accordance with this, this study demonstrates that Treg cell 
expansion is grossly impaired in mice which lack RORγt, the lineage defining 
transcription factor for ILC3s, although this needs to be repeated in mice which 




interaction partner between Treg cells and ILC3s, and suggests a new candidate: 
Nrp-1. The TNF receptor and co-stimulatory molecule DR3 was also shown to be 
highly expressed by ILC3s, and therefore may have a role in modulating their activity 
(Figure 6.1). A technique for inducing ILC proliferation was successfully applied to 









Figure 6.1: Dendritic Cell and Group 3 Innate Lymphoid Cell-derived signals 
which may contribute to regulatory T cell survival and function. Previous studies 
have demonstrated a clear role for TCR and CD28 in the survival of Treg cells, and 
signals between Nrp-1 and Sema4a have also been implicated (black arrows). This 
study has provided evidence for a role for OX40 and CD30 in Treg cell expansion, as 
well as function, and considers the role of ILC3s which are able to provide signals 
through these receptors, as well as the TCR (grey arrows). In addition, this study 
demonstrated that Nrp-1 is highly expressed by ILC3s, as well as the TNF receptor 
DR3. The former has the potential to form homotypic interactions which could provide 
signals through Nrp-1 expressed by Treg cells, and the latter may contribute to ILC3 
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